{"ResultsReport": {"xmlns": "http://integration.foundationmedicine.com/reporting", "xmlnsxsi": "http://www.w3.org/2001/XMLSchema_instance", "xsischemaLocation": "http://integration.foundationmedicine.com/reporting http://integration.foundationmedicine.com/reporting/ResultsReport.2.1.xsd", "CustomerInformation": {"ReferenceID": "01_2022_00019440", "CSN": null, "TRF": "ORD_1321248_01", "MRN": "27866553", "PhysicianId": "109266", "NPI": "International"}, "ResultsPayload": {"FinalReport": {"xmlnsxsd": "http://www.w3.org/2001/XMLSchema", "StagingId": "1058477", "clinicalId": "1059848", "xsinoNamespaceSchemaLocation": "http://integration.foundationmedicine.com/reporting/ClinicalReport.1.1.xsd", "Application": {"ApplicationSettings": {"ApplicationSetting": {"Name": "Statement", "Value": null}}}, "DemographicCorrectionDate": null, "ReportId": "ORD_1321248_01", "SampleName": "US1270842.01", "Version": "0", "Sample": {"FM_Id": "ORD_1321248_01", "SampleId": "US1270842.01", "BlockId": "S111-07318A", "TRFNumber": "ORD_1321248_01", "TestType": "FoundationOne CDx             ", "SpecFormat": "FFPE", "ReceivedDate": "2022_03_14", "processSites": {"processSite": [{"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "LC"}, {"address": "150 Second St., 1st Floor, Cambridge, MA 02141", "cliaNumber": "22D2027531", "locationID": "1", "locationName": "Cambridge", "processID": "1", "processName": "Extracted DNA"}]}, "TumorPurity": "60", "SpecimenLocation": "nan"}, "PMI": {"ReportId": "S111-98804", "MRN": "27866553", "FullName": "\u6c5f\u7f8e\u971e", "FirstName": "27866553", "LastName": "27866553", "SubmittedDiagnosis": "Glioblastom, Cerebrum", "Gender": "Female", "DOB": "1951_11_17", "OrderingMD": "\u8a31\u79c9\u6b0a", "OrderingMDId": "109266", "Pathologist": "\u5468\u5fb7\u76c8", "CopiedPhysician1": null, "MedFacilName": "Taipei Veterans General Hospital", "MedFacilID": "205872", "SpecSite": "Brain", "CollDate": "2022_02_23", "ReceivedDate": "2022-03-25 00:00:00", "CountryOfOrigin": "TW", "TumorType": "Diffuse Glioma"}, "PertinentNegatives": {"PertinentNegative": [{"Gene": "EGFR"}, {"Gene": "IDH1"}, {"Gene": "PDGFRA"}]}, "Summaries": {"alterationCount": "20", "clinicalTrialCount": "17", "resistiveCount": "0", "sensitizingCount": "2"}, "VariantProperties": {"VariantProperty": [{"geneName": "ATR", "isVUS": "true", "variantName": "D701E"}, {"geneName": "BRCA2", "isVUS": "true", "variantName": "G2528R"}, {"geneName": "DAXX", "isVUS": "true", "variantName": "E457del"}, {"geneName": "EPHB4", "isVUS": "true", "variantName": "R206Q"}, {"geneName": "MAP3K1", "isVUS": "true", "variantName": "T948_T949del"}, {"geneName": "MSH6", "isVUS": "true", "variantName": "K1358fs*2"}, {"geneName": "NBN", "isVUS": "true", "variantName": "V346M"}, {"geneName": "NOTCH3", "isVUS": "true", "variantName": "R75Q"}, {"geneName": "RAD52", "isVUS": "true", "variantName": "amplification"}, {"geneName": "TBX3", "isVUS": "true", "variantName": "A562V"}]}, "priorTests": null, "Genes": {"Gene": [{"Name": "CCND2", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "CCND2 encodes the protein cyclin D2, which binds and regulates the cyclin_dependent kinases that control cell cycle progression, and is a downstream target of cancer signaling pathways including hedgehog and PI3K (Katoh and Katoh, 2009; 19860666, White et al., 2006; 16301994). CCND2 has been reported to be amplified in cancer (Gao et al., 2013; 23550210), and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). In the TCGA dataset, CCND2 amplification was observed in 3% of glioblastoma cases (cBio_Brennan et al., 2013; 24120142) and 7% of lower grade glioma cases (Cancer Genome Atlas Research Network., 2015; 26061751). CCND2 amplification has been reported in 3% of primary malignant gliomas in one study, with amplification occurring in one anaplastic astrocytoma and two glioblastoma cases (B\u00fcschges et al., 1999; 10416984). CCND2 mRNA expression has been reported to be increased in higher grade (3 and 4) astrocytoma tumors as compared to lower grade tumors (Kheirollahi et al., 2011; 20077038). Cyclin D2 has been reported to be the main cyclin expressed in glioblastoma stem cells (GSCs) but was barely detectable in differentiated glioblastoma cells (Koyama_Nasu et al., 2013; 22964630). Cyclin D2, in complex with CDK4/6, has been reported to be involved in the cell cycle progression of undifferentiated GSCs, but not differentiated GSCs, and to be involved in their tumorigenicity (Koyama_Nasu et al., 2013; 22964630). High CCND2 nuclear expression at the time of initial surgery for patients with glioblastoma was reported to significantly associate with early mortality in a multivariate analysis of 72 patients (Bouchart et al., 2019; 31568682). Although preclinical studies suggest that cyclin D2 activates CDK4/6 (Busk et al., 2005; 15707582, Busk, 2003; 12695654), it is unknown whether CCND2 amplification or activating mutation predicts response to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib. Clinical studies of CDK4/6 inhibitors have shown the most promise for estrogen receptor_positive breast cancer (Finn et al., 2014; 25524798, DeMichele et al., 2014; 25501126).", "Include": "true", "ClinicalTrialNote": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04282031", "Include": "true"}, {"nctId": "NCT04594005", "Include": "true"}, {"nctId": "NCT04391595", "Include": "true"}, {"nctId": "NCT02933736", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT03158389", "Include": "true"}, {"nctId": "NCT02981940", "Include": "true"}, {"nctId": "NCT02896335", "Include": "true"}, {"nctId": "NCT03310879", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "PIK3CA", "Include": "true", "Alterations": {"Alteration": {"Name": "E542V", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "E542V"}}, "Interpretation": "PIK3CA encodes p110_alpha, which is the catalytic subunit of phosphatidylinositol 3_kinase (PI3K). The PI3K pathway is involved in cell signaling that regulates a number of critical cellular functions, including cell growth, proliferation, differentiation, motility, and survival (Samuels et al., 2005; 15950905, Engelman, 2009; 19629070). PIK3CA alterations that have been characterized as activating, such as observed here, are predicted to be oncogenic (Kang et al., 2005; 15647370, Ikenoue et al., 2005; 15930273, Gymnopoulos et al., 2007; 17376864, Horn et al., 2008; 18317450, Rudd et al., 2011; 21266528, Hon et al., 2012; 22120714, Burke et al., 2012; 22949682, Wu et al., 2009; 19915146, Dbouk et al., 2010; 2103068, Dan et al., 2010; 20530683, Oda et al., 2008; 18829572, Zhao and Vogt, 2008; 18794883, Lui et al., 2013; 23619167, Ross et al., 2013; 22430209, Riviere et al., 2012; 22729224, Shibata et al., 2009; 19394761, Droguluk et al., 2015; 26627007,Croessmann et al., 2018; 29284706, Ng et al., 2018; 29533785, Spangle et al., 2020; 32929011, Chen et al., 2018; 29636477, Jin et al., 2021; 34779417). PIK3CA mutations have been reported in 9% of glioblastoma (GBM) samples analyzed in the TCGA dataset (cBio_Brennan et al., 2013; 24120142), and other studies report the incidence of PIK3CA mutations in primary GBMs as 5_18% (Gallia et al., 2006; 17050665, Broderick et al., 2004; 15289301, El_Habr et al., 2010; 20569675). One study detected PIK3CA mutation in 16% (36/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). PIK3CA mutations have been reported in 5_23% of high_grade gliomas (including glioblastomas, anaplastic astrocytomas, and anaplastic oligodendrogliomas) (El_Habr et al., 2010; 20569675, Gallia et al., 2006; 17050665, Broderick et al., 2004; 15289301, Derakhshandeh_Peykar et al., 2011; 22026810, Cancer Genome Atlas Research Network., 2008; 18772890). While another study did not observe PIK3CA mutations in low_grade astrocytomas or in anaplastic astrocytomas, it did report high ERK and AKT activity (El_Habr et al., 2010; 20569675). One study found that PIK3CA mutation in glioblastoma (GBM) was associated with shorter median PFS in both a discovery cohort (6.9 vs. 12.4 months, HR=2.89, p=0.01) and in the TCGA cohort (6.1 vs. 9 months, p=0.008), but was not consistently associated with median OS (Tanaka et al., 2019; 31036078). In a study of IDH_wildtype GBM, patients with alterations in PI3K class I genes (PIK3CA, PIK3R1, PIK3CG, and PIK3R2) had significantly longer OS (20.0 months altered vs. 16.9 months wildtype, HR=0.62, p=0.002) and PFS (11.0 months altered vs. 7.4 months wildtype, p=0.0043); patients with PIK3CA alterations experienced an improved OS but this association was not highly significant (20.0 months altered vs. 18.1 months wildtype, p=0.0407)(Yan et al. 2020; DOI:10.1200/PO.19.00385). Clinical and preclinical data in various tumor types indicate that PIK3CA activating alterations may predict sensitivity to therapies targeting PI3K (Fritsch et al., 2014; 24608574, Juric et al., 2018; 29401002, Gallant et al., 2019; 30793038), AKT (Andre et al., 2019; 31091374, Smyth et al., 2021; 33863913), or mTOR (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452). In the Phase 2 MATCH trial for patients with PIK3CA_mutated solid tumors, 28% (18/65) of patients experienced PFS lasting at least 6 months after treatment with taselisib; however, no ORs were observed in this study (Krop et al., 2018; ASCO Abstract 101). A separate Phase 1b study of taselisib in combination with the CDK4/6 inhibitor palbociclib for patients with PIK3CA_mutated solid tumors reported an ORR of 0% (n=12) and a DCR of 17% (2/12) (Pascual et al., 2021; 32958578). In a Phase 1 trial of the dual PI3K/mTOR kinase inhibitor apitolisib, 79% (11/14) of patients with PIK3CA_mutated advanced solid tumors experienced disease control (3 PRs, 8 SDs) (Dolly et al., 2016; 26787751). The PI3K inhibitor alpelisib demonstrated an ORR of 6.0% (8/134) and a DCR of 58% (78/134) in a study for patients with PIK3CA_mutated solid tumors (Juric et al., 2018; 2941002). However, the PI3K inhibitor copanlisib exhibited limited efficacy in PIK3CA_mutated tumors (Santin et al., 2020; 31934607, Patnaik et al., 2016; 27672108).", "Include": "true", "ClinicalTrialNote": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Therapies": {"Therapy": [{"Name": null, "GenericName": "Everolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Everolimus is an orally available mTOR inhibitor that is FDA approved to treat renal cell carcinoma (RCC) following antiangiogenic therapy; pancreatic neuroendocrine tumors; and well_differentiated non_functional neuroendocrine tumors of the lung or gastrointestinal tract. Everolimus is also approved to treat either renal angiomyolipoma or subependymal giant cell astrocytoma in association with tuberous sclerosis complex (TSC). Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> Case reports have described 2 children with PIK3CA_mutated diffuse glioma or glioneuronal tumor who benefited from treatment with everolimus alone or in combination with temozolomide (Gojo et al., 2020; 31998633, McNall_Knapp et al., 2020; SNO Abstract LGG_47), and 1 adult with glioblastoma (GBM) harboring PIK3CA mutation and KRAS amplification who experienced disease progression with single_agent everolimus (Blumenthal et al., 2016; 27531351). A Phase 2 trial of radiotherapy (RT), temozolomide (TMZ), and bevacizumab followed by everolimus and bevacizumab reported that 61% (31/51) of patients with newly diagnosed glioblastoma had objective responses with a median progression_free survival (PFS) of 11.3 months and median overall survival (OS) of 13.9 months (Hainsworth et al., 2012; 22706484). A Phase 2 study of everolimus combined with TMZ and RT for the treatment of newly diagnosed glioblastoma reported a median PFS of 6.4 months and median OS of 15.8 months (Ma et al., 2014; 25526733). A Phase 1 trial of everolimus plus TMZ for patients with newly diagnosed or progressive glioblastoma reported partial responses (PR) in 11% (3/28) and stable disease (SD) in 57% (16/28) of cases (Mason et al., 2011; 22160854). A pilot study of everolimus with gefitinib in patients with recurrent glioblastoma reported 14% (3/22) PRs, 36% (8/22) SDs, and median PFS and OS of 2.6 months and 5.8 months, respectively (Kreisl et al., 2009; 19018475). Everolimus treatment achieved SD in 45% (5/11) of pediatric patients with heavily pretreated low_grade CNS tumors; median PFS of these responses was 14 months (Segal et al., 2016; ISPNO Abstract EPT_21). Whereas frequent adverse events precluded a recommended Phase 2 dose and schedule for the combination of trametinib and everolimus in a Phase 1b trial for solid tumors (Tolcher et al., 2014; 25344362), a retrospective study for heavily pretreated patients with solid tumors reported tolerable regimens of the combination for 23/31 patients, with 16 patients treated >3 months and evaluable patients achieving a median PFS of 6.5 months (Patterson et al., 2018; AACR Abstract 3891). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}, {"Name": null, "GenericName": "Temsirolimus", "FDAApproved": "false", "Rationale": "<p><b>Approved Indications:</b> Temsirolimus is an intravenous mTOR inhibitor that is FDA approved for the treatment of advanced renal cell carcinoma. Please see the drug label for full prescribing information. </p> <p><b>Gene Association:</b> On the basis of clinical evidence (Park et al., 2016; 27105424, Lim et al., 2016; 26859683, Hou et al., 2014; 25426553, Varnier et al., 2019; 31351267, Janku et al., 2014; 24440717, Moroney et al., 2012; 22927482, Basho et al., 2017; 27893038, Moroney et al., 2011; 21890452), PIK3CA activating mutations may predict sensitivity to mTOR inhibitors such as everolimus and temsirolimus. Studies have reported modest activity of these therapies as single agents (ORRs of 0_4%), but improved activity has been observed when they are combined with other agents such as bevacizumab and doxorubicin (ORRs of 25_44%), for patients with PIK3CA_mutated solid tumors (Janku et al., 2014; 24440717, Janku et al., 2013; 23066039, Janku et al., 2012; 22271473, Janku et al., 2011; 21216929, Moroney et al., 2012; 22927482, Moroney et al., 2011; 21890452, Basho et al., 2017; 27893038, Moulder et al., 2015; 25878190, Byeon et al., 2020; doi: 10.21037/tcr.2020.04.07). </p> <p><b>Supporting Data:</b> A Phase 1, dose_escalation trial combining temsirolimus and radiation/temozolomide therapy, with or without adjuvant temozolomide monotherapy, in patients with newly diagnosed glioblastoma reported no clinical responses but 24/25 patients experienced a period of stable disease; increased infection rates were noted with this regimen (Sarkaria et al., 2010; 20921209). A Phase 1/2 trial of temsirolimus in combination with sorafenib in glioblastoma was terminated at the Phase 2 interim analysis after patients failed to meet the primary endpoint of 6 month progression_free survival; significant toxicity was also observed in the combination therapy, even at low doses of temsirolimus (Lee et al., 2012; 23099651). A Phase 2 study showed that addition of temsirolimus to bevacizumab therapy in patients with recurrent glioblastoma did not add clinical benefit (Lassen et al., 2013; 23564811). A Phase 2 clinical trial of temsirolimus in pediatric glioma reported disease stabilization in 7/17 patients including one patient with anaplastic astrocytoma (Geoerger et al., 2012; 22033322). A Phase 1/2 study of temsirolimus in combination with erlotinib reported 6% (1/16) complete responses, 6% (1/16) partial responses, and 12.5% (2/16) instances of stable disease in patients with anaplastic glioma (Wen et al., 2014; 24470557). </p>", "ApprovedUses": null, "Effect": "Sensitizing", "Include": "true", "IncludeInSummary": "true", "ReferenceLinks": null}]}, "ReferenceLinks": null, "ClinicalTrialLinks": {"ClinicalTrialLink": [{"nctId": "NCT04589845", "Include": "true"}, {"nctId": "NCT03239015", "Include": "true"}, {"nctId": "NCT04337463", "Include": "true"}, {"nctId": "NCT04803318", "Include": "true"}, {"nctId": "NCT03772561", "Include": "true"}, {"nctId": "NCT04801966", "Include": "true"}, {"nctId": "NCT04632992", "Include": "true"}, {"nctId": "NCT03994796", "Include": "true"}, {"nctId": "NCT03711058", "Include": "true"}, {"nctId": "NCT03158389", "Include": "true"}]}}}, "ReferenceLinks": null}, {"Name": "ATRX", "Include": "true", "Alterations": {"Alteration": {"Name": "D1940fs*14", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "D1940fs*14"}}, "Interpretation": "ATRX encodes a SWI/SNF chromatin remodeling protein implicated in histone variant H3.3 deposition, transcriptional regulation, and telomere maintenance (Clynes et al., 2013; 23916100, Ratnakumar and Bernstein, 2013; 23249563). ATRX inactivation or loss of expression is associated with alternative lengthening of telomeres (ALT)(Lovejoy et al., 2012; 22829774, Bower et al, 2012; 23185534; Heaphy et al., 2011; 21719641, Liau et al., 2015; 25229770). Alterations that disrupt the ADD domain (aa 167_270) or helicase domain (aa 2010_2280) of ATRX are predicted to result in loss of ATRX function (Nan et al., 2007; 17296936, Garrick et al., 2004; 14729260, Eustermann et al., 2011; 21666677); however, the loss of ATRX function is not sufficient to induce ALT, which requires other undetermined factors (Clynes et al., 2013; 23916100, Flynn et al., 2015; 25593184). Germline mutations in ATRX give rise to alpha_thalassemia X_linked intellectual disability syndrome (ATR_X syndrome)(Gibbons et al., 1995; 7697714). Somatic mutation of ATRX has been reported in a number of solid tumor types, often associated with ALT (Heaphy et al., 2011; 21719641). ATRX mutation correlating with ALT has been reported in 10_20% of pancreatic neuroendocrine tumors (PNETs)(Singhi et al., 2015; USCAP Abstract 1797)(Jiao et al., 2011; 21252315, Heaphy et al., 2011; 21719641), 12.6% of pheochromocytomas and paragangliomas (Fishbein et al., 2015; 25608029), and 48% of adolescent and young adult (AYA) patients with glioblastoma (GBM) or neuroblastoma (Morosini et al., 2014; ASCO Abstract 11008)(Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). ATRX loss in PNET (Singhi et al., 2015; USCAP Abstract 1797)(Marinoni et al., 2014; 24148618) and melanoma (Qadeer et al., 2014; 24468746) and mutation in other neuroendocrine tumors (Fishbein et al., 2015; 25608029) is associated with poor prognosis. Pediatric patients with high_grade glioma and ATRX mutation were shown to have more aggressive disease but are more responsive to treatment with double_strand break therapy (Koschmann et al., 2016; 26936505). ATRX mutation or loss of expression is more frequent in Grade 2/3 astrocytoma and secondary GBM than primary GBM, oligodendroglioma, and oligoastrocytoma (Kannan et al., 2012; 23104868, Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301) and has been proposed as a distinguishing biomarker (Haberler and W\u00f6hrer, 2014; 24559763, Reuss et al., 2014; 25427834, Sahm et al., 2014; 25143301). ATRX mutation has not been detected in concurrence with MYCN amplification in glioma and neuroblastoma (Cheung et al., 2012; 22416102, Molenaar et al., 2012; 22367537, Pugh et al., 2013; 23334666, Cheung and Dyer, 2013; 23702928). Low_grade gliomas with both IDH1/2 mutation and ATRX mutation are associated with worse prognosis than those with IDH1/2 mutation but no ATRX mutation (Haberler and W\u00f6hrer, 2014; 24559763). Loss of ATRX protein expression has been reported in 33_39% of incidences of leiomyosarcoma (LMS) associating with ALT, a poor prognostic factor across all LMS subtypes, and with poor prognosis in extrauterine LMS but not in uterine LMS (Singhi et al., 2015; USCAP Abstract 93)(Liau et al., 2015; 25229770). No targeted therapies are available to directly address ATRX inactivation. Based on preclinical (Liang et al., 2020; 31551363, Garbarino et al., 2021; 34118569) and limited clinical data (Cole et al., 2021; AACR Abstract CT059), ATRX alterations may confer sensitivity to combination strategies involving WEE1 inhibition. In a Phase 2 study evaluating the WEE1 inhibitor adavosertib plus irinotecan for the treatment of pediatric patients with neuroblastoma, prolonged SD was reported for 44% (4/9) of patients with ATRX_deficient tumors and responses were seen in two tumors that had evidence of ALT (Cole et al., 2021; AACR Abstract CT059). Preclinical evidence also suggests that ATRX deficiency may impart sensitivity to synthetic lethal approaches involving PARP inhibition and irinotecan (George et al., 2020; 32846370), combined PARP and ATR inhibition (Garbarino et al., 2021; 34118569), or double_strand break_induction with agents such as doxorubicin, irinotecan, and topotecan (Koschmann et al., 2016; 26936505); however, these approaches have not been demonstrated clinically.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "CDKN2A/B", "Include": "true", "Alterations": {"Alteration": {"Name": "p16INK4a loss exons 1_2 and p14ARF loss exon 2", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "p16INK4a loss exons 1_2 and p14ARF loss exon 2"}}, "Interpretation": "CDKN2A encodes two different, unrelated tumor suppressor proteins, p16INK4a and p14ARF, whereas CDKN2B encodes the tumor suppressor p15INK4b (Quelle et al., 1995; 8521522, Sharpless, 2005; 15878778). Both p15INK4b and p16INK4a bind to and inhibit CDK4 and CDK6, thereby maintaining the growth_suppressive activity of the Rb tumor suppressor; loss or inactivation of either p15INK4b or p16INK4a contributes to dysregulation of the CDK4/6_cyclin_Rb pathway and loss of cell cycle control (Gazzeri et al., 1998; 9484839, Roussel, 1999; 10498883). The tumor suppressive functions of p14ARF involve stabilization and activation of p53, via a mechanism of MDM2 inhibition (Sherr et al., 2005; 16869746, Ozenne et al., 2010; 20549699). One or more alterations observed here are predicted to result in p16INK4a loss of function (Ruas et al., 1999; 10498896, Jones et al., 2007; 17909018, Haferkamp et al., 2008; 18843795, Huot et al., 2002; 12417717, Rizos et al., 2001; 11518711, Gombart et al., 1997; 9324288, Yang et al., 1995; 7780957, Parry and Peters, 1996; 8668202, Greenblatt et al., 2003; 12606942, Yarbrough et al., 1999; 10491434, Poi et al., 2001; 11255261, Byeon et al., 1998; 9660926, Kannengiesser et al., 2009; 19260062, Lal et al., 2000; 10719365, Koh et al., 1995; 7777061, McKenzie et al., 2010; 20340136, Miller et al., 2011; 21462282, Arap et al., 1997; 905385, Scaini et al., 2014; 24659262, Jenkins et al., 2013; 23190892, Walker et al., 1999; 10389768, Rutter et al., 2003; 12853981). One or more alterations seen here are predicted to result in p14ARF loss of function (Rizos et al., 2001; 11518711, Itahana and Zhang, 2008; 18538737, Zhang and Xiong, 1999; 10360174, Zhang et al., 1998; 9529249, Rutter et al., 2003; 12853981). Concurrent putative homozygous deletion of CDKN2A and CDKN2B has been reported in 35% of patients with gliomas (cBio_Ceccarelli et al., 2016; 26824661) and detected more frequently in patients with glioblastoma multiforme (GBM; 58%)(cBio_Brennan et al., 2013; 24120142) than in those with lower grade gliomas (13%) (cBioPortal, Sep 2021)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). In other studies, loss of CDKN2A/B by deletion has been reported in up to 78% of astrocytomas (including anaplastic astrocytomas and GBM) (Verhaak et al., 2010; 20129251, Sottoriva et al., 2013; 23412337, Weber et al., 2007; 16909113). A study found homozygous deletion of both p16INK4a and p14ARF in 26% (13/50) of glioblastomas (GBMs); 18% (9/50) of cases showed homozygous deletion of the p14ARF_encoding locus alone (Nakamura et al., 2001; 11303791). One study detected CDKN2A/B loss in 69% (161/232) and mutation in 2.6% (6/232) of IDH_wildtype GBM samples analyzed (Yan et al. 2020; DOI:10.1200/PO.19.00385). Decreased p14ARF and p16INK4a expression levels were found to be tightly associated in a study of glioma samples (Chakravarti et al., 2001; 11489817). Homozygous deletion of the genomic region including CDKN2A and CDKN2B has been found to be associated with poor prognosis in GBM and likely serves as an early event in GBM progression (Feng et al., 2012; 21713760, Sottoriva et al., 2013; 23412337). In addition, expression of p16INK4a has been found to be lower in patients with high grade malignant gliomas compared to patients with low grade gliomas, and loss of p16INK4a expression has been associated with shorter overall survival in pilocytic astrocytomas (Raabe et al., 2011; 21636552, Liu et al., 2011; 21843312). Preclinical data suggest that tumors with loss of p16INK4a function may be sensitive to CDK4/6 inhibitors, such as abemaciclib, ribociclib, and palbociclib (Konecny et al., 2011; 21278246, Katsumi et al., 2011; 21871868, Cen et al., 2012; 22711607, Logan et al., 2013; 23898052). Although case studies have reported that patients with breast cancer or uterine leiomyosarcoma harboring CDKN2A loss responded to palbociclib treatment (Elvin et al., 2017; 28283584, Gao et al., 2015; 26715889), multiple other clinical studies have shown no significant correlation between p16INK4a loss or inactivation and therapeutic benefit of these agents (Gopalan et al., 2014; ASCO Abstract 8077, Peguero et al., 2016; ASCO Abstract 2528, Konecny et al., 2016; ASCO Abstract 5557)(DeMichele et al., 2014; 25501126, Finn et al., 2015; 25524798, Infante et al., 2016; 27542767, Johnson et al., 2014; 24797823); it is not known whether CDK4/6 inhibitors would be beneficial in this case. Although preclinical studies have suggested that loss of p14ARF function may be associated with reduced sensitivity to MDM2 inhibitors (Van Maerken et al., 2011; 21460101, Gamble et al., 2012; 21725357), the clinical relevance of p14ARF as a predictive biomarker is not clear. Germline CDKN2A mutation is associated with melanoma_pancreatic cancer syndrome, a condition marked by increased risk of developing malignant melanoma and/or pancreatic cancer (Whelan et al., 1995; 7666917). Mutation carriers within families may develop either or both types of cancer, and melanoma cases may be referred to as familial or hereditary melanoma (Hansson, 2010; 20687502, Hogg et al., 1998; 9479083). CDKN2A is the most implicated gene in familial melanoma, with germline mutations present in 16% to 20% of familial melanoma cases (De Unamuno et al., 2018; 29543703, Soura et al., 2016; 26892650, Huerta et al., 2018; 29405243). CDKN2A alteration has also been implicated in familial melanoma_astrocytoma syndrome, an extremely rare tumor association characterized by dual predisposition to melanoma and nervous system tumors (Kaufman et al., 1993; 8414022, Bahuau et al., 1998; 9622062, Chan et al., 2017; 28699883). In the appropriate clinical context, germline testing of CDKN2A is recommended.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF23", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "FGF23 encodes a member of the fibroblast growth factor protein family that plays a central role in phosphate homeostasis (Jonsson et al., 2003; 12711740). Overexpression of FGF23 by tumor cells can cause hypophosphatemia through excessive renal phosphate clearance (Shimada et al., 2001; 11344269), while germline gain_of_function (protein stabilizing) mutations in FGF23 cause autosomal dominant hypophosphatemic rickets (Xu and White, 2005; 15863037). FGF23 alterations have been reported with highest incidence in uterine carcinosarcoma (7.0%), ovarian carcinoma (6.5%), testicular germ cell cancer (5.4%), cutaneous melanoma (5.0%), low_grade glioma (4.9%), lung squamous cell carcinoma (4.5%), sarcoma (4.3%), colorectal adenocarcinoma (4.2%), lung adenocarcinoma (3.7%), and head and neck squamous cell carcinoma (3.4%) (cBioPortal, 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). There are no targeted therapies that directly address genomic alterations in FGF23. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "FGF6", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "FGF6 (also known as HST_2) encodes a member of the fibroblast growth factor protein family and is hypothesized to play a role in muscle tissue regeneration (Neuhaus et al., 2003; 12917328) by signaling through FGFR4, and to a lesser extent FGFR1 and FGFR2 (Ornitz et al., 1996; 8663044). FGF6 expression has been observed in several cancers (Iida et al., 1992; 1549352, Ropiquet et al., 2000; 10945637, Niini et al., 2002; 12399964) and was shown to be oncogenic in preclinical models (Marics et al., 1989; 2649847, Iida et al., 1992; 1549352). FGF6 has been reported as amplified in cancer (Gao et al., 2013; 23550210) and may be biologically relevant in this context (Zack et al., 2013; 24071852, Beroukhim et al., 2010; 20164920). Somatic alterations affecting FGF6 are infrequently documented, with the highest rates reported in penile cancer (4%), cutaneous melanoma (1_3%), stomach carcinoma (1_3%) and colorectal cancer (1%) (cBioPortal, COSMIC, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210, Tate et al., 2019; 30371878). Amplification of FGF6 has been frequently observed in testicular germ cell cancer (5%) and ovarian serous cystadenocarcinoma (5%), and in 2_6% of lower_grade gliomas, glioblastomas, sarcomas, breast invasive carcinomas, uterine carcinosarcomas, lung squamous cell carcinomas (SCC), head and neck SCC, pancreatic adenocarcinomas, and esophageal carcinomas (cBioPortal, Jan 2022) (Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). FGF6 is co_localized with FGF23 and CCND2 at chromosomal locus 12p13 and has been reported to be co_amplified with these genes in 1.3% of patients with breast cancer (Parish et al., 2015; 25950492). FGF6 expression has been reported in 54% (14/26) of prostate cancer samples, which also frequently express FGFR4 (Ropiquet et al., 2000; 10945637). FGF6 expression has also been observed in 71% (12/17) of patients with childhood acute lymphoblastic leukemia (Niini et al., 2002; 12399964). There are no targeted therapies that directly address genomic alterations in FGF6. Inhibitors of FGF receptors, however, are undergoing clinical trials in a number of different cancers. Limited data suggest that pan_FGFR inhibitors show activity in FGF amplified cancers; following treatment with a selective pan_FGFR inhibitor, a patient with head and neck squamous cell carcinoma (HNSCC) and amplification of 11q13 (FGF3, FGF4, FGF19) and 12p13 (FGF6 and FGF23) experienced a radiologic CR (Dumbrava et al., 2018; doi/full/10.1200/PO.18.00100).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "KDM5A", "Include": "true", "Alterations": {"Alteration": {"Name": "amplification", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "true", "name": "amplification"}}, "Interpretation": "KDM5A encodes a lysine_specific histone demethylase that potentiates the expression of genes involved in cellular proliferation, senescence, angiogenesis, and migration (Zeng et al., 2010; 19850045, Chicas et al., 2012; 22615382, Teng et al., 2013; 23722541, Li et al., 2014; 24716659, Lin et al., 2014; 25537453). KDM5A overexpression alters the transcriptional regulation of cell cycle genes, including CCND1, and a variety of cyclin_dependent kinase inhibitors (CDKIs), including CDKN1A, CDKN1B, and CDKN2A, and results in cell cycle progression (Zeng et al., 2010; 19850045, Teng et al., 2013; 23722541, Liang et al., 2013; 23922798, Jiping et al., 2013; 23794145, Vieira et al., 2014; 24200674, Li et al., 2014; 24716659). Additionally, elevated KDM5A expression and associated chromatin remodeling has been implicated in resistance to various tyrosine kinase inhibitors in vitro, including erlotinib and gefitinib (Sharma et al., 2010; 20371346, Dannenberg et al., 2010; 20371339, Hou et al., 2012; 22937203). KDM5A amplification has been reported with the highest incidence in TCGA datasets in ovarian serous cystadenocarcinoma (7.2%), testicular germ cell cancer (5.8%), pancreatic adenocarcinoma (4.3%), and lung squamous cell carcinoma (3.9%) (cBioPortal, Jan 2022)(Cerami et al., 2012; 22588877, Gao et al., 2013; 23550210). Elevated levels of KDM5A expression have also been reported in a range of solid tumor types (Hou et al., 2012; 22937203, Liang et al., 2013; 23922798, Teng et al., 2013; 23722541, Paolicchi et al., 2013; 23266085, Vieira et al., 2014; 24200674, Li et al., 2014; 24716659), and fusion of KDM5A to NUP98 has been documented in acute myeloid leukemia (van Zutven et al., 2006; 16419055, Wang et al., 2009; 19430464). KDM5A expression is significantly correlated with HIF_1alpha and VEGF expression, as well as tumor size, angiogenesis, and poor patient prognosis in lung cancer (Qi et al., 2014; 25162518). There are no targeted therapies available to directly address genomic alterations in KDM5A. However, multiple preclinical studies have identified potential targets in KDM5A amplified or activated cells that may respond to therapy. KDM5A_mediated chromatin remodeling induces CCND1 expression and represses CDKI expression (Zeng et al., 2010; 19850045, Teng et al., 2013; 23722541, Liang et al., 2013; 23922798, Jiping et al., 2013; 23794145, Vieira et al., 2014; 24200674); therefore, KDM5A activation or amplification may sensitize cells to CDK4/CDK6 inhibitors. Drug_resistant cell populations, characterized by elevated KDM5A expression, responded to histone deacetylase (HDAC) inhibition (Sharma et al., 2010; 20371346), suggesting that HDAC inhibitors may be a potential therapeutic option. KDM5A also induces expression of VEGF and promotes angiogenesis, oncogenic transformation, and tumorigenesis, which can be inhibited by KDM5A knockdown (Li et al., 2014; 24716659, Qi et al., 2014; 25162518), suggesting that tumors harboring KDM5A amplification may be sensitive to angiogenesis inhibitors, including kinase inhibitors that target the VEGF receptors, such as sunitinib, sorafenib, vandetanib, ponatinib, cabozantinib, regorafenib, pazopanib, and axitinib. However, these inhibitors have yet to be extensively tested in the context of KDM5A amplification or activation; therefore, it is not known if these therapeutic strategies are relevant.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Microsatellite status", "Include": "true", "Alterations": {"Alteration": {"Name": "MS_Stable", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "MS_Stable"}}, "Interpretation": "Microsatellite instability (MSI) is a condition of genetic hypermutability that generates excessive amounts of short insertion/deletion mutations in the genome; it generally occurs at microsatellite DNA sequences and is caused by a deficiency in DNA mismatch repair (MMR) in the tumor (Kocarnik et al., 2015; 26337942). Defective MMR and consequent MSI occur as a result of genetic or epigenetic inactivation of one of the MMR pathway proteins, primarily MLH1, MSH2, MSH6, or PMS2 (You et al., 2010; 21081928, Bairwa et al., 2014; 24623249, Kocarnik et al., 2015; 26337942). This sample is microsatellite_stable (MSS), equivalent to the clinical definition of an MSS tumor: one with mutations in none of the tested microsatellite markers (Boland et al., 1998; 9823339, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). MSS status indicates MMR proficiency and typically correlates with intact expression of all MMR family proteins (Kocarnik et al., 2015; 26337942, Bairwa et al., 2014; 24623249, Pawlik et al., 2004; 15528785, Boland and Goel, 2010; 20420947). Low_level MSI has been reported in 5_9% of glioblastoma (GBM) samples (Martinez et al., 2004; 15331927, Martinez et al., 2005; 15672285, Martinez et al., 2007; 17498554). A large_scale study did not find high_level microsatellite instability (MSI_H) in any of 129 GBM samples (Martinez et al., 2004; 15331927), although a small_scale study reported MSI_H in 4 of 15 pediatric GBMs and 1 of 12 adult GBMs (Szybka et al., 2003; 12908754). The frequency of MSI has been reported to be increased in relapsed compared to primary GBM (Martinez et al., 2004; 15331927), in GBMs with a previous lower grade astrocytoma (Martinez et al., 2005; 15672285), and in giant cell GBM compared to classic GBM (Martinez et al., 2007; 17498554). On the basis of clinical evidence, MSS tumors are significantly less likely than MSI_H tumors to respond to anti_PD_1 immune checkpoint inhibitors (Gatalica et al., 2014; 25392179, Kroemer et al., 2015; 26140250, Lal et al., 2015; 25949894), including approved therapies nivolumab and pembrolizumab (Overman et al., 2016; ASCO Abstract 3501, Le et al., 2015; 26028255). In a retrospective analysis of 361 patients with solid tumors treated with pembrolizumab, 3% were MSI_H and experienced a significantly higher ORR compared with non_MSI_H cases (70% vs. 12%, p=0.001) (Ayers et al., 2016; ASCO_SITC Abstract P60).", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "TP53", "Include": "true", "Alterations": {"Alteration": {"Name": "R273C", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "R273C"}}, "Interpretation": "Functional loss of the tumor suppressor p53, which is encoded by the TP53 gene, is common in aggressive advanced cancers (Brown et al., 2009; 19935675). Alterations such as seen here may disrupt TP53 function or expression (Joerger and Fersht, 2008; 18410249, Kato et al., 2003; 12826609, Kamada et al., 2011; 20978130, Zerdoumi et al., 2017; 28472496, Yamada et al., 2007; 17690113). In the TCGA dataset, TP53 alterations have been reported in 35% of glioblastomas (GBMs), with a high incidence in pediatric and secondary GBMs and a low incidence in primary GBMs (Cancer Genome Atlas Research Network., 2008; 18772890, Jha et al., 2011; 22089350). One study detected TP53 alterations in 31% (73/232) of IDH_wildtype GBM samples analyzed, with most of the events being mutations (Yan et al. 2020; DOI:10.1200/PO.19.00385). TP53 mutations have been reported in 18_40% of astrocytoma samples, and preferentially in anaplastic astrocytoma; one study reported TP53 loss of function and partially/fully functional mutations in 15% and 25% of anaplastic astrocytomas, respectively (Uno et al., 2005; 15914282, Uno et al., 2006; 16711514, Lass et al., 2012; 22844452, Faria et al., 2012; 23009112, Milinkovic et al., 2013; 24358143, Galatro et al., 2013; 23613880). Some studies suggest that the presence of a TP53 mutation is correlated with a favorable prognosis in patients with glioblastoma (GBM) (Schmidt et al., 2002; 11939587). One study reported that TP53 alterations were associated with poorer OS (12.9 months altered vs. 19.7 months wildtype, HR=1.58, p=0.0054) in IDH_wildtype GBM (Yan et al. 2020; DOI:10.1200/PO.19.00385). Mutation of TP53 is thought to be an early step in the tumorigenesis of astrocytomas, which can progress into anaplastic astrocytoma and then glioblastoma through gain of other genetic abnormalities such as loss of CDKN2A or RB1, followed by loss of PTEN (Nozaki et al., 1999; 11550308). There are no approved therapies to address TP53 mutation or loss. However, tumors with TP53 loss of function alterations may be sensitive to the WEE1 inhibitor adavosertib (Hirai et al., 2010; 20107315, Bridges et al., 2011; 21799033, Rajeshkumar et al., 2011; 21389100, Osman et al., 2015; 25504633), or p53 gene therapy and immunotherapeutics such as SGT_53 (Xu et al., 2002; 12489850, Xu et al., 2001; 11713371, Camp et al., 2013; 23470564, Kim et al., 2015; 25240597, Pirollo et al., 2016; 27357628) and ALT_801 (Hajdenberg et al., 2012; ASCO Abstract e15010). In a Phase 1 study, adavosertib in combination with gemcitabine, cisplatin, or carboplatin elicited PRs in 9.7% and SDs in 53% of patients with solid tumors; the response rate was 21% (4/19) for patients with TP53 mutations versus 12% (4/33) for patients who were TP53 wildtype (Leijen et al., 2016; 27601554). A Phase 2 trial of adavosertib in combination with chemotherapy (gemcitabine, carboplatin, paclitaxel, or doxorubicin) reported a 32% (30/94, 3 CR) ORR and a 73% (69/94) DCR for patients with platinum_refractory TP53_mutated ovarian, Fallopian tube, or peritoneal cancer (Moore et al., 2019; ASCO Abstract 5513). A smaller Phase 2 trial of adavosertib in combination with carboplatin achieved a 43% (9/21, 1 CR) ORR and a 76% (16/21) DCR for patients with platinum_refractory TP53_mutated ovarian cancer (Leijen et al., 2016; 27998224). The combination of adavosertib with paclitaxel and carboplatin for patients with TP53_mutated ovarian cancer also significantly increased PFS compared with paclitaxel and carboplatin alone (Oza et al., 2015; ASCO Abstract 5506). In the Phase 2 VIKTORY trial, patients with TP53_mutated metastatic and/or recurrent gastric cancer experienced a 24% (6/25) ORR with adavosertib combined with paclitaxel (Lee et al., 2019; 31315834). A Phase 1 trial of neoadjuvant adavosertib in combination with cisplatin and docetaxel for head and neck squamous cell carcinoma (HNSCC) elicited a 71% (5/7) response rate for patients with TP53 alterations (Mendez et al., 2018; 29535125). The Phase 2 FOCUS4_C trial for patients with TP53_ and RAS_mutated colorectal cancer reported improvement in PFS (3.61 vs. 1.87 months, HR=0.35, p=0.0022), but not OS (14.0 vs 12.8 months, p=0.93), following adavosertib treatment compared with active monitoring (Seligmann et al., 2021; 34538072). In a Phase 1b clinical trial of SGT_53 in combination with docetaxel for patients with solid tumors, 75% (9/12) of evaluable patients experienced clinical benefit, including 2 confirmed and 1 unconfirmed PRs and 2 instances of SD with significant tumor shrinkage (Pirollo et al., 2016; 27357628). Missense mutations leading to TP53 inactivation may also be sensitive to therapies that reactivate mutated p53 such as APR_246 (Gourley et al., 2016; ASCO Abstract 5571, Lehmann et al., 2012; 22965953, Mohell et al., 2015; 26086967, Franssonet al., 2016; 27179933). In a Phase 1b trial for patients with p53_positive high_grade serous ovarian cancer, APR_246 combined with carboplatin and pegylated liposomal doxorubicin achieved a 52% (11/21) response rate and 100% DCR (Gourley et al., 2016; ASCO Abstract 5571). ATR inhibitor treatment of chronic lymphocytic leukemia (CLL) cells with biallelic inactivation of TP53 suppressed cell viability, promoted DNA damage, and attenuated xenograft growth in preclinical studies (Kwok et al., 2016; 26563132, Boudny et al., 2019; 30975914); however, ATR inhibitors as monotherapy had little effect on these parameters in solid tumor models in other preclinical studies (Dillon et al., 2017; 28062704, Middleton et al., 2018; 30127241). Therefore, it is unclear whether TP53 inactivation predicts sensitivity to ATR inhibition. One or more of the TP53 variants observed here has been described in the ClinVar database as a likely pathogenic or pathogenic germline mutation (by an expert panel or multiple submitters) associated with Li_Fraumeni syndrome (ClinVar, Sep 2021)(Landrum et al., 2018; 29165669). Follow_up germline testing would be needed to distinguish whether the finding in this patient is somatic or germline. Germline mutations in TP53 are associated with the very rare autosomal dominant disorder Li_Fraumeni syndrome and the early onset of many cancers (Bougeard et al., 2015; 26014290, Sorrell et al., 2013; 23355100, Nichols et al., 2001; 11219776), including sarcomas (Kleihues et al., 1997; 9006316, Gonzalez et al., 2009; 19204208). Estimates for the prevalence of germline TP53 mutations in the general population range from 1:5,000 (Lalloo et al., 2003; 12672316) to 1:20,000 (Gonzalez et al., 2009; 19204208). For pathogenic TP53 mutations identified during tumor sequencing, the rate of germline mutations was 1% in the overall population and 6% in tumors arising before age 30 (Mandelker et al., 2019; 31050713). In the appropriate clinical context, germline testing of TP53 is recommended. Variants seen in this gene have been reported to occur in clonal hematopoiesis (CH), an age_related process in which hematopoietic stem cells acquire somatic mutations that allow for clonal expansion (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838, Xie et al., 2014; 25326804, Acuna_Hidalgo et al., 2017; 28669404, Severson et al., 2018; 29678827, Fuster et al., 2018; 29420212). CH in this gene has been associated with increased mortality, risk of coronary heart disease, risk of ischemic stroke, and risk of secondary hematologic malignancy (Jaiswal et al., 2014; 25426837, Genovese et al., 2014; 25426838). Clinical management of patients with CH in this gene may include monitoring for hematologic changes and reduction of controllable risk factors for cardiovascular disease (Steensma., 2018; 30504320). Comprehensive genomic profiling of solid tumors detects nontumor alterations that are due to CH (Severson et al., 2018; 29678827, Chabon et al., 2020; 32269342, Razavi et al., 2019; 31768066). Patient_matched peripheral blood mononuclear cell sequencing is required to conclusively determine if this alteration is present in tumor or is secondary to CH.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}, {"Name": "Tumor Mutation Burden", "Include": "true", "Alterations": {"Alteration": {"Name": "05", "AlterationProperties": {"AlterationProperty": {"isEquivocal": "false", "name": "05"}}, "Interpretation": "Tumor mutation burden (TMB, also known as mutation load) is a measure of the number of somatic protein_coding base substitution and insertion/deletion mutations occurring in a tumor specimen. TMB is affected by a variety of causes, including exposure to mutagens such as ultraviolet light in melanoma (Pfeifer et al., 2005; 15748635, Hill et al., 2013; 23875803) and cigarette smoke in lung cancer (Pfeifer et al., 2002; 12379884, Rizvi et al., 2015; 25765070), treatment with temozolomide_based chemotherapy in glioma (Johnson et al., 2014; 24336570, Choi et al., 2018; 29452419), mutations in the proofreading domains of DNA polymerases encoded by the POLE and POLD1 genes (Cancer Genome Atlas Research Network, 2013; 23636398, Briggs and Tomlinson, 2013; 23447401, Heitzer and Tomlinson, 2014; 24583393, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919), and microsatellite instability (MSI) (Cancer Genome Atlas Research Network, 2013; 23636398, Cancer Genome Atlas Network, 2012; 22810696, Roberts and Gordenin, 2014; 25568919). This sample harbors a TMB below levels that would be predicted to be associated with sensitivity to PD_1_ or PD_L1_targeting immune checkpoint inhibitors, alone or in combination with other agents (Touat et al., 2020; 32322066, Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556, Lukas et al., 2018; 30073642). Glioblastoma (GBM) harbors a median TMB of 2.7 mutations per megabase (muts/Mb), and 4.2% of cases have high TMB (>20 muts/Mb)(FMI_Chalmers et al., 2017; 28420421). For pediatric patients, high TMB has been reported in a subset of high_grade gliomas, frequently in association with mutations in mismatch repair or proofreading genes and in TP53, whereas BRAF alterations or other oncogene fusions were observed more frequently in brain tumors harboring low TMB (Patel et al., 2020; 32386112, Johnson et al., 2017; 28912153). Increased TMB has been reported to correlate with higher tumor grade in glioma (Draaisma et al., 2015; 26699864) and glioblastoma (GBM) tissue samples with biallelic mismatch repair deficiency (bMMRD) (Bouffet et al., 2016; 27001570), as well as with shorter OS of patients with diffuse glioma (Wang et al., 2020; 32164609). On the basis of clinical evidence in solid tumors, increased TMB may be associated with greater sensitivity to immunotherapeutic agents, including anti_PD_L1 (Legrand et al., 2018; ASCO Abstract 12000, Samstein et al., 2019; 30643254, Goodman et al., 2017; 28835386, Goodman et al., 2019; 31405947), anti_PD_1 therapies (Cristescu et al., 2018; 30309915, Goodman et al., 2017; 28835386, Samstein et al., 2019; 30643254, Marabelle et al., 2019; ESMO Abstract 11920, Goodman et al., 2019; 31405947), and combination nivolumab and ipilimumab (Ready et al., 2019; 30785829, Hellmann et al., 2018; 29658845, Hellmann et al., 2018; 29657128, Rizvi et al., 2017; WCLC Abstract 1106, Hellmann et al., 2018; 29731394, Rozeman et al., 2021; 33558721, Hodi et al., 2019; AACR abstract CT037, Lee et al., 2019; ASCO Abstract 641, Sharma et al., 2020; 32916128). In glioma, a lack of association between TMB and clinical benefit from immune checkpoint inhibitors has been reported (Kamiya_Matsuoka et al., 2019; ESMO Abstract 393O, Zhao et al., 2019; 30742119, Samstein et al., 2019; 30643254, Touat et al., 2020; 32322066). However, multiple case studies have reported that patients with ultramutated gliomas driven by POLE mutations have benefited from treatment with anti_PD_1 (Bouffet et al., 2016; 27001570, Johanns et al., 2016; 27683556) or anti_PD_L1 (Lukas et al., 2018; 30073642) therapies. Therefore, although increased TMB alone may not be a strong biomarker for PD_1 or PD_L1 inhibitors in this cancer type, these agents may have efficacy for patients with glioma harboring both high TMB and POLE mutation.", "Include": "true", "ClinicalTrialNote": null, "Therapies": null, "ReferenceLinks": null, "ClinicalTrialLinks": null}}, "ReferenceLinks": null}]}, "Trials": {"Trial": [{"Gene": "CCND2", "Alteration": "amplification", "Title": "A Study of BPI_1178 in Patients With Advanced Solid Tumor and HR+/HER2_ Breast Cancer", "StudyPhase": "PHASE 1/2", "Target": "CDK6, CDK4, ER, Aromatase", "Locations": "Shanghai (China)", "NCTID": "NCT04282031", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "CDK4/6 Tumor, Abemaciclib, Paclitaxel", "StudyPhase": "PHASE 1/2", "Target": "CDK4, CDK6", "Locations": "Seoul (Korea, Republic of)", "NCTID": "NCT04594005", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, ERK1, ERK2", "Locations": "Arizona", "NCTID": "NCT04391595", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients", "StudyPhase": "PHASE null", "Target": "CDK6, CDK4", "Locations": "Arizona", "NCTID": "NCT02933736", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "NCT Neuro Master Match _ N\u00b2M\u00b2 (NOA_20)", "StudyPhase": "PHASE 1/2", "Target": "ALK, RET, CDK4, CDK6, mTOR, MDM2, PD_L1, SMO", "Locations": "Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)", "NCTID": "NCT03158389", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "A Study of Abemaciclib in Recurrent Glioblastoma", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Utah, California, Massachusetts", "NCTID": "NCT02981940", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Palbociclib In Progressive Brain Metastases", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT02896335", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "CCND2", "Alteration": "amplification", "Title": "Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D_type Cyclins or Amplification of CDK4 or CDK6", "StudyPhase": "PHASE 2", "Target": "CDK4, CDK6", "Locations": "Massachusetts", "NCTID": "NCT03310879", "Note": "CCND2 amplification or activation may predict sensitivity to CDK4/6 inhibitors.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "Tumor_Agnostic Precision Immuno_Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, RET, PD_L1, AKTs, ERBB2, MDM2, PI3K_alpha", "Locations": "Zhongzheng Dist. (Taiwan), Taipei City (Taiwan), Taoyuan County (Taiwan), Tainan (Taiwan), Hong Kong (Hong Kong), Seoul (Korea, Republic of), Xi an (China), Tianjin (China), Beijing (China), Chengdu City (China)", "NCTID": "NCT04589845", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event", "StudyPhase": "PHASE 2", "Target": "EGFR, ERBB4, ERBB2, PARP, mTOR, MET, ROS1, RET, VEGFRs, BRAF, CDK4, CDK6", "Locations": "Shanghai (China)", "NCTID": "NCT03239015", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "ATG_008 Combined With Toripalimab in Advanced Solid Tumors", "StudyPhase": "PHASE null", "Target": "mTORC1, mTORC2, PD_1", "Locations": "Chongqing (China), Chengdu (China)", "NCTID": "NCT04337463", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "Trametinib Combined With Everolimus and Lenvatinib for Recurrent/Refractory Advanced Solid Tumors", "StudyPhase": "PHASE 2", "Target": "mTOR, FGFRs, RET, PDGFRA, VEGFRs, KIT, MEK", "Locations": "Guangzhou (China)", "NCTID": "NCT04803318", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "Phase I Study of AZD5363 + Olaparib + Durvalumab in Patients With Advanced or Metastatic Solid Tumor Malignancies", "StudyPhase": "PHASE 1", "Target": "PARP, AKTs, PD_L1", "Locations": "Singapore (Singapore)", "NCTID": "NCT03772561", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study", "StudyPhase": "PHASE null", "Target": "CDK4, CDK6, PI3K_alpha, PD_L1, MEK, PARP, PD_1, BRAF", "Locations": "Melbourne (Australia)", "NCTID": "NCT04801966", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, PD_L1, ERBB2, PI3K_alpha, RET, AKTs", "Locations": "Alaska, Washington, Oregon, California, Idaho", "NCTID": "NCT04632992", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "Genetic Testing in Guiding Treatment for Patients With Brain Metastases", "StudyPhase": "PHASE 2", "Target": "TRKB, ALK, TRKC, ROS1, TRKA, CDK4, CDK6, PI3K, mTOR", "Locations": "Washington, Oregon, Idaho, Montana", "NCTID": "NCT03994796", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "Study of PI3Kinase Inhibition (Copanlisib) and Anti_PD_1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch_repair Proficient (MSS) Colorectal Cancer", "StudyPhase": "PHASE 1/2", "Target": "PD_1, PI3K", "Locations": "Maryland", "NCTID": "NCT03711058", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}, {"Gene": "PIK3CA", "Alteration": "E542V", "Title": "NCT Neuro Master Match _ N\u00b2M\u00b2 (NOA_20)", "StudyPhase": "PHASE 1/2", "Target": "ALK, RET, CDK4, CDK6, mTOR, MDM2, PD_L1, SMO", "Locations": "Berlin (Germany), Dresden (Germany), Regensburg (Germany), Bochum (Germany), Frankfurt am Main (Germany), Essen (Germany), Mainz (Germany), Heidelberg (Germany), Cologne (Germany), Mannheim (Germany)", "NCTID": "NCT03158389", "Note": "PIK3CA activating mutations may lead to activation of the PI3K_AKT_mTOR pathway and may therefore indicate sensitivity to inhibitors of this pathway. Strong clinical data support sensitivity of PIK3CA_mutated solid tumors to the PI3K_alpha inhibitor alpelisib.", "Include": "true"}]}, "References": {"Reference": [{"number": "0", "ReferenceId": "19860666", "FullCitation": "Katoh Y, et al. Curr. Mol. Med. (2009) pmid: 19860666", "Include": "true"}, {"number": "1", "ReferenceId": "16301994", "FullCitation": "White PC, et al. Oncogene (2006) pmid: 16301994", "Include": "true"}, {"number": "2", "ReferenceId": "23550210", "FullCitation": "Gao J, et al. Sci Signal (2013) pmid: 23550210", "Include": "true"}, {"number": "3", "ReferenceId": "24071852", "FullCitation": "Zack TI, et al. Nat. Genet. (2013) pmid: 24071852", "Include": "true"}, {"number": "4", "ReferenceId": "20164920", "FullCitation": "Beroukhim R, et al. Nature (2010) pmid: 20164920", "Include": "true"}, {"number": "5", "ReferenceId": "24120142", "FullCitation": "Brennan CW, et al. Cell (2013) pmid: 24120142", "Include": "true"}, {"number": "6", "ReferenceId": "26061751", "FullCitation": "Cancer Genome Atlas Research Network, et al. N. Engl. J. Med. (2015) pmid: 26061751", "Include": "true"}, {"number": "7", "ReferenceId": "10416984", "FullCitation": "B\u00fcschges R, et al. Brain Pathol. (1999) pmid: 10416984", "Include": "true"}, {"number": "8", "ReferenceId": "20077038", "FullCitation": "Kheirollahi M, et al. Med. Oncol. (2011) pmid: 20077038", "Include": "true"}, {"number": "9", "ReferenceId": "22964630", "FullCitation": "Koyama_Nasu R, et al. Oncogene (2013) pmid: 22964630", "Include": "true"}, {"number": "10", "ReferenceId": "31568682", "FullCitation": "Bouchart C, et al. Cancer Med (2019) pmid: 31568682", "Include": "true"}, {"number": "11", "ReferenceId": "15707582", "FullCitation": "Busk PK, et al. Exp. Cell Res. (2005) pmid: 15707582", "Include": "true"}, {"number": "12", "ReferenceId": "12695654", "FullCitation": "Busk PK, et al. Cell Cycle () pmid: 12695654", "Include": "true"}, {"number": "13", "ReferenceId": "25524798", "FullCitation": "Finn RS, et al. Lancet Oncol. (2015) pmid: 25524798", "Include": "true"}, {"number": "14", "ReferenceId": "25501126", "FullCitation": "DeMichele A, et al. Clin. Cancer Res. (2015) pmid: 25501126", "Include": "true"}, {"number": "15", "ReferenceId": "15950905", "FullCitation": "Samuels Y, et al. Cancer Cell (2005) pmid: 15950905", "Include": "true"}, {"number": "16", "ReferenceId": "19629070", "FullCitation": "Nat. Rev. Cancer (2009) pmid: 19629070", "Include": "true"}, {"number": "17", "ReferenceId": "15647370", "FullCitation": "Kang S, et al. Proc. Natl. Acad. Sci. U.S.A. (2005) pmid: 15647370", "Include": "true"}, {"number": "18", "ReferenceId": "15930273", "FullCitation": "Ikenoue T, et al. Cancer Res. (2005) pmid: 15930273", "Include": "true"}, {"number": "19", "ReferenceId": "17376864", "FullCitation": "Gymnopoulos M, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17376864", "Include": "true"}, {"number": "20", "ReferenceId": "18317450", "FullCitation": "Horn S, et al. Oncogene (2008) pmid: 18317450", "Include": "true"}, {"number": "21", "ReferenceId": "21266528", "FullCitation": "Rudd ML, et al. Clin. Cancer Res. (2011) pmid: 21266528", "Include": "true"}, {"number": "22", "ReferenceId": "22120714", "FullCitation": "Hon WC, et al. Oncogene (2012) pmid: 22120714", "Include": "true"}, {"number": "23", "ReferenceId": "22949682", "FullCitation": "Burke JE, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22949682", "Include": "true"}, {"number": "24", "ReferenceId": "19915146", "FullCitation": "Wu H, et al. Proc. Natl. Acad. Sci. U.S.A. (2009) pmid: 19915146", "Include": "true"}, {"number": "25", "ReferenceId": "2103068", "FullCitation": "Laurenti R, et al. Rev Saude Publica (1990) pmid: 2103068", "Include": "true"}, {"number": "26", "ReferenceId": "20530683", "FullCitation": "Dan S, et al. Cancer Res. (2010) pmid: 20530683", "Include": "true"}, {"number": "27", "ReferenceId": "18829572", "FullCitation": "Oda K, et al. Cancer Res. (2008) pmid: 18829572", "Include": "true"}, {"number": "28", "ReferenceId": "18794883", "FullCitation": "Zhao L, et al. Oncogene (2008) pmid: 18794883", "Include": "true"}, {"number": "29", "ReferenceId": "23619167", "FullCitation": "Lui VW, et al. Cancer Discov (2013) pmid: 23619167", "Include": "true"}, {"number": "30", "ReferenceId": "22430209", "FullCitation": "Ross RL, et al. Oncogene (2013) pmid: 22430209", "Include": "true"}, {"number": "31", "ReferenceId": "22729224", "FullCitation": "Rivi\u00e8re JB, et al. Nat. Genet. (2012) pmid: 22729224", "Include": "true"}, {"number": "32", "ReferenceId": "19394761", "FullCitation": "Shibata T, et al. Cancer Lett. (2009) pmid: 19394761", "Include": "true"}, {"number": "33", "ReferenceId": "26627007", "FullCitation": "Dogruluk T, et al. Cancer Res. (2015) pmid: 26627007", "Include": "true"}, {"number": "34", "ReferenceId": "29284706", "FullCitation": "Croessmann S, et al. Clin. Cancer Res. (2018) pmid: 29284706", "Include": "true"}, {"number": "35", "ReferenceId": "29533785", "FullCitation": "Ng PK, et al. Cancer Cell (2018) pmid: 29533785", "Include": "true"}, {"number": "36", "ReferenceId": "32929011", "FullCitation": "Spangle JM, et al. (2020) pmid: 32929011", "Include": "true"}, {"number": "37", "ReferenceId": "29636477", "FullCitation": "Chen L, et al. Nat Commun (2018) pmid: 29636477", "Include": "true"}, {"number": "38", "ReferenceId": "34779417", "FullCitation": "Jin N, et al. J Clin Invest (2021) pmid: 34779417", "Include": "true"}, {"number": "39", "ReferenceId": "17050665", "FullCitation": "Gallia GL, et al. Mol. Cancer Res. (2006) pmid: 17050665", "Include": "true"}, {"number": "40", "ReferenceId": "15289301", "FullCitation": "Broderick DK, et al. Cancer Res. (2004) pmid: 15289301", "Include": "true"}, {"number": "41", "ReferenceId": "20569675", "FullCitation": "El_Habr EA, et al. Clin. Neuropathol. () pmid: 20569675", "Include": "true"}, {"number": "42", "ReferenceId": "22026810", "FullCitation": "Derakhshandeh_Peykar P, et al. J. Neurogenet. (2011) pmid: 22026810", "Include": "true"}, {"number": "43", "ReferenceId": "18772890", "FullCitation": "Nature (2008) pmid: 18772890", "Include": "true"}, {"number": "44", "ReferenceId": "31036078", "FullCitation": "Tanaka S, et al. Acta Neuropathol Commun (2019) pmid: 31036078", "Include": "true"}, {"number": "45", "ReferenceId": "24608574", "FullCitation": "Fritsch C, et al. Mol. Cancer Ther. (2014) pmid: 24608574", "Include": "true"}, {"number": "46", "ReferenceId": "29401002", "FullCitation": "Juric D, et al. J. Clin. Oncol. (2018) pmid: 29401002", "Include": "true"}, {"number": "47", "ReferenceId": "30793038", "FullCitation": "Gallant JN, et al. NPJ Precis Oncol (2019) pmid: 30793038", "Include": "true"}, {"number": "48", "ReferenceId": "31091374", "FullCitation": "Andr\u00e9 F, et al. N. Engl. J. Med. (2019) pmid: 31091374", "Include": "true"}, {"number": "49", "ReferenceId": "33863913", "FullCitation": "Smyth LM, et al. NPJ Breast Cancer (2021) pmid: 33863913", "Include": "true"}, {"number": "50", "ReferenceId": "27105424", "FullCitation": "Park HS, et al. PLoS ONE (2016) pmid: 27105424", "Include": "true"}, {"number": "51", "ReferenceId": "26859683", "FullCitation": "Lim SM, et al. Oncotarget (2016) pmid: 26859683", "Include": "true"}, {"number": "52", "ReferenceId": "25426553", "FullCitation": "Hou MM, et al. Oncotarget (2014) pmid: 25426553", "Include": "true"}, {"number": "53", "ReferenceId": "31351267", "FullCitation": "Varnier R, et al. Eur J Cancer (2019) pmid: 31351267", "Include": "true"}, {"number": "54", "ReferenceId": "24440717", "FullCitation": "Janku F, et al. Cell Rep (2014) pmid: 24440717", "Include": "true"}, {"number": "55", "ReferenceId": "22927482", "FullCitation": "Moroney J, et al. Clin. Cancer Res. (2012) pmid: 22927482", "Include": "true"}, {"number": "56", "ReferenceId": "27893038", "FullCitation": "Basho RK, et al. JAMA Oncol (2017) pmid: 27893038", "Include": "true"}, {"number": "57", "ReferenceId": "21890452", "FullCitation": "Moroney JW, et al. Clin. Cancer Res. (2011) pmid: 21890452", "Include": "true"}, {"number": "58", "ReferenceId": "32958578", "FullCitation": "Pascual J, et al. Cancer Discov (2021) pmid: 32958578", "Include": "true"}, {"number": "59", "ReferenceId": "26787751", "FullCitation": "Dolly SO, et al. Clin. Cancer Res. (2016) pmid: 26787751", "Include": "true"}, {"number": "60", "ReferenceId": "2941002", "FullCitation": "Aust Fam Physician (1986) pmid: 2941002", "Include": "true"}, {"number": "61", "ReferenceId": "31934607", "FullCitation": "Santin AD, et al. Gynecol Oncol Rep (2020) pmid: 31934607", "Include": "true"}, {"number": "62", "ReferenceId": "27672108", "FullCitation": "Patnaik A, et al. Ann. Oncol. (2016) pmid: 27672108", "Include": "true"}, {"number": "63", "ReferenceId": "23916100", "FullCitation": "Clynes D, et al. Trends Biochem. Sci. (2013) pmid: 23916100", "Include": "true"}, {"number": "64", "ReferenceId": "23249563", "FullCitation": "Ratnakumar K, et al. Epigenetics (2013) pmid: 23249563", "Include": "true"}, {"number": "65", "ReferenceId": "22829774", "FullCitation": "Lovejoy CA, et al. PLoS Genet. (2012) pmid: 22829774", "Include": "true"}, {"number": "66", "ReferenceId": "23185534", "FullCitation": "Bower K, et al. PLoS ONE (2012) pmid: 23185534", "Include": "true"}, {"number": "67", "ReferenceId": "21719641", "FullCitation": "Heaphy CM, et al. Science (2011) pmid: 21719641", "Include": "true"}, {"number": "68", "ReferenceId": "25229770", "FullCitation": "Liau JY, et al. Am. J. Surg. Pathol. (2015) pmid: 25229770", "Include": "true"}, {"number": "69", "ReferenceId": "17296936", "FullCitation": "Nan X, et al. Proc. Natl. Acad. Sci. U.S.A. (2007) pmid: 17296936", "Include": "true"}, {"number": "70", "ReferenceId": "14729260", "FullCitation": "Garrick D, et al. Gene (2004) pmid: 14729260", "Include": "true"}, {"number": "71", "ReferenceId": "21666677", "FullCitation": "Eustermann S, et al. Nat. Struct. Mol. Biol. (2011) pmid: 21666677", "Include": "true"}, {"number": "72", "ReferenceId": "25593184", "FullCitation": "Flynn RL, et al. Science (2015) pmid: 25593184", "Include": "true"}, {"number": "73", "ReferenceId": "7697714", "FullCitation": "Gibbons RJ, et al. Cell (1995) pmid: 7697714", "Include": "true"}, {"number": "74", "ReferenceId": "21252315", "FullCitation": "Jiao Y, et al. Science (2011) pmid: 21252315", "Include": "true"}, {"number": "75", "ReferenceId": "25608029", "FullCitation": "Fishbein L, et al. Nat Commun (2015) pmid: 25608029", "Include": "true"}, {"number": "76", "ReferenceId": "22416102", "FullCitation": "Cheung NK, et al. JAMA (2012) pmid: 22416102", "Include": "true"}, {"number": "77", "ReferenceId": "22367537", "FullCitation": "Molenaar JJ, et al. Nature (2012) pmid: 22367537", "Include": "true"}, {"number": "78", "ReferenceId": "23334666", "FullCitation": "Pugh TJ, et al. Nat. Genet. (2013) pmid: 23334666", "Include": "true"}, {"number": "79", "ReferenceId": "23702928", "FullCitation": "Cheung NK, et al. Nat. Rev. Cancer (2013) pmid: 23702928", "Include": "true"}, {"number": "80", "ReferenceId": "24148618", "FullCitation": "Marinoni I, et al. Gastroenterology (2014) pmid: 24148618", "Include": "true"}, {"number": "81", "ReferenceId": "24468746", "FullCitation": "Qadeer ZA, et al. J. Invest. Dermatol. (2014) pmid: 24468746", "Include": "true"}, {"number": "82", "ReferenceId": "26936505", "FullCitation": "Koschmann C, et al. Sci Transl Med (2016) pmid: 26936505", "Include": "true"}, {"number": "83", "ReferenceId": "23104868", "FullCitation": "Kannan K, et al. Oncotarget (2012) pmid: 23104868", "Include": "true"}, {"number": "84", "ReferenceId": "24559763", "FullCitation": "Haberler C, et al. Clin. Neuropathol. () pmid: 24559763", "Include": "true"}, {"number": "85", "ReferenceId": "25427834", "FullCitation": "Reuss DE, et al. Acta Neuropathol. (2015) pmid: 25427834", "Include": "true"}, {"number": "86", "ReferenceId": "25143301", "FullCitation": "Sahm F, et al. Acta Neuropathol. (2014) pmid: 25143301", "Include": "true"}, {"number": "87", "ReferenceId": "31551363", "FullCitation": "Liang J, et al. Cancer Res (2020) pmid: 31551363", "Include": "true"}, {"number": "88", "ReferenceId": "34118569", "FullCitation": "Garbarino J, et al. Transl Oncol (2021) pmid: 34118569", "Include": "true"}, {"number": "89", "ReferenceId": "32846370", "FullCitation": "George SL, et al. EBioMedicine (2020) pmid: 32846370", "Include": "true"}, {"number": "90", "ReferenceId": "12711740", "FullCitation": "Jonsson KB, et al. N. Engl. J. Med. (2003) pmid: 12711740", "Include": "true"}, {"number": "91", "ReferenceId": "11344269", "FullCitation": "Shimada T, et al. Proc. Natl. Acad. Sci. U.S.A. (2001) pmid: 11344269", "Include": "true"}, {"number": "92", "ReferenceId": "15863037", "FullCitation": "Yu X, et al. Cytokine Growth Factor Rev. (2005) pmid: 15863037", "Include": "true"}, {"number": "93", "ReferenceId": "22588877", "FullCitation": "Cerami E, et al. Cancer Discov (2012) pmid: 22588877", "Include": "true"}, {"number": "94", "ReferenceId": "26337942", "FullCitation": "Kocarnik JM, et al. Gastroenterol Rep (Oxf) (2015) pmid: 26337942", "Include": "true"}, {"number": "95", "ReferenceId": "21081928", "FullCitation": "You JF, et al. Br. J. Cancer (2010) pmid: 21081928", "Include": "true"}, {"number": "96", "ReferenceId": "24623249", "FullCitation": "Bairwa NK, et al. Methods Mol. Biol. (2014) pmid: 24623249", "Include": "true"}, {"number": "97", "ReferenceId": "9823339", "FullCitation": "Boland CR, et al. Cancer Res. (1998) pmid: 9823339", "Include": "true"}, {"number": "98", "ReferenceId": "15528785", "FullCitation": "Pawlik TM, et al. Dis. Markers (2004) pmid: 15528785", "Include": "true"}, {"number": "99", "ReferenceId": "20420947", "FullCitation": "Boland CR, et al. Gastroenterology (2010) pmid: 20420947", "Include": "true"}, {"number": "100", "ReferenceId": "15331927", "FullCitation": "Martinez R, et al. Oncology (2004) pmid: 15331927", "Include": "true"}, {"number": "101", "ReferenceId": "15672285", "FullCitation": "Martinez R, et al. J. Cancer Res. Clin. Oncol. (2005) pmid: 15672285", "Include": "true"}, {"number": "102", "ReferenceId": "17498554", "FullCitation": "Martinez R, et al. Cancer Genet. Cytogenet. (2007) pmid: 17498554", "Include": "true"}, {"number": "103", "ReferenceId": "12908754", "FullCitation": "Szybka M, et al. Clin. Neuropathol. () pmid: 12908754", "Include": "true"}, {"number": "104", "ReferenceId": "25392179", "FullCitation": "Gatalica Z, et al. Cancer Epidemiol. Biomarkers Prev. (2014) pmid: 25392179", "Include": "true"}, {"number": "105", "ReferenceId": "26140250", "FullCitation": "Kroemer G, et al. Oncoimmunology (2015) pmid: 26140250", "Include": "true"}, {"number": "106", "ReferenceId": "25949894", "FullCitation": "Lal N, et al. Oncoimmunology (2015) pmid: 25949894", "Include": "true"}, {"number": "107", "ReferenceId": "26028255", "FullCitation": "Le DT, et al. N. Engl. J. Med. (2015) pmid: 26028255", "Include": "true"}, {"number": "108", "ReferenceId": "12917328", "FullCitation": "Neuhaus P, et al. Mol. Cell. Biol. (2003) pmid: 12917328", "Include": "true"}, {"number": "109", "ReferenceId": "8663044", "FullCitation": "Ornitz DM, et al. J. Biol. Chem. (1996) pmid: 8663044", "Include": "true"}, {"number": "110", "ReferenceId": "1549352", "FullCitation": "Iida S, et al. Oncogene (1992) pmid: 1549352", "Include": "true"}, {"number": "111", "ReferenceId": "10945637", "FullCitation": "Ropiquet F, et al. Cancer Res. (2000) pmid: 10945637", "Include": "true"}, {"number": "112", "ReferenceId": "12399964", "FullCitation": "Niini T, et al. Leukemia (2002) pmid: 12399964", "Include": "true"}, {"number": "113", "ReferenceId": "2649847", "FullCitation": "Marics I, et al. Oncogene (1989) pmid: 2649847", "Include": "true"}, {"number": "114", "ReferenceId": "30371878", "FullCitation": "Tate JG, et al. Nucleic Acids Res. (2019) pmid: 30371878", "Include": "true"}, {"number": "115", "ReferenceId": "25950492", "FullCitation": "Parish A, et al. Cell Cycle (2015) pmid: 25950492", "Include": "true"}, {"number": "116", "ReferenceId": "15748635", "FullCitation": "Pfeifer GP, et al. Mutat. Res. (2005) pmid: 15748635", "Include": "true"}, {"number": "117", "ReferenceId": "23875803", "FullCitation": "Hill VK, et al. Annu Rev Genomics Hum Genet (2013) pmid: 23875803", "Include": "true"}, {"number": "118", "ReferenceId": "12379884", "FullCitation": "Pfeifer GP, et al. Oncogene (2002) pmid: 12379884", "Include": "true"}, {"number": "119", "ReferenceId": "25765070", "FullCitation": "Rizvi NA, et al. Science (2015) pmid: 25765070", "Include": "true"}, {"number": "120", "ReferenceId": "24336570", "FullCitation": "Johnson BE, et al. Science (2014) pmid: 24336570", "Include": "true"}, {"number": "121", "ReferenceId": "29452419", "FullCitation": "Choi S, et al. Neuro_oncology (2018) pmid: 29452419", "Include": "true"}, {"number": "122", "ReferenceId": "23636398", "FullCitation": "Cancer Genome Atlas Research Network, et al. Nature (2013) pmid: 23636398", "Include": "true"}, {"number": "123", "ReferenceId": "23447401", "FullCitation": "Briggs S, et al. J. Pathol. (2013) pmid: 23447401", "Include": "true"}, {"number": "124", "ReferenceId": "24583393", "FullCitation": "Heitzer E, et al. Curr. Opin. Genet. Dev. (2014) pmid: 24583393", "Include": "true"}, {"number": "125", "ReferenceId": "22810696", "FullCitation": "Nature (2012) pmid: 22810696", "Include": "true"}, {"number": "126", "ReferenceId": "25568919", "FullCitation": "Roberts SA, et al. Nat. Rev. Cancer (2014) pmid: 25568919", "Include": "true"}, {"number": "127", "ReferenceId": "32322066", "FullCitation": "Touat M, et al. Nature (2020) pmid: 32322066", "Include": "true"}, {"number": "128", "ReferenceId": "30742119", "FullCitation": "Zhao J, et al. Nat. Med. (2019) pmid: 30742119", "Include": "true"}, {"number": "129", "ReferenceId": "30643254", "FullCitation": "Samstein RM, et al. Nat. Genet. (2019) pmid: 30643254", "Include": "true"}, {"number": "130", "ReferenceId": "27001570", "FullCitation": "Bouffet E, et al. J. Clin. Oncol. (2016) pmid: 27001570", "Include": "true"}, {"number": "131", "ReferenceId": "27683556", "FullCitation": "Johanns TM, et al. Cancer Discov (2016) pmid: 27683556", "Include": "true"}, {"number": "132", "ReferenceId": "30073642", "FullCitation": "Lukas RV, et al. J. Neurooncol. (2018) pmid: 30073642", "Include": "true"}, {"number": "133", "ReferenceId": "28420421", "FullCitation": "Chalmers ZR, et al. Genome Med (2017) pmid: 28420421", "Include": "true"}, {"number": "134", "ReferenceId": "32386112", "FullCitation": "Patel RR, et al. Pediatr Blood Cancer (2020) pmid: 32386112", "Include": "true"}, {"number": "135", "ReferenceId": "28912153", "FullCitation": "Johnson A, et al. Oncologist (2017) pmid: 28912153", "Include": "true"}, {"number": "136", "ReferenceId": "26699864", "FullCitation": "Draaisma K, et al. Acta Neuropathol Commun (2015) pmid: 26699864", "Include": "true"}, {"number": "137", "ReferenceId": "32164609", "FullCitation": "Wang L, et al. BMC Cancer (2020) pmid: 32164609", "Include": "true"}, {"number": "138", "ReferenceId": "28835386", "FullCitation": "Goodman AM, et al. Mol. Cancer Ther. (2017) pmid: 28835386", "Include": "true"}, {"number": "139", "ReferenceId": "31405947", "FullCitation": "Goodman AM, et al. Cancer Immunol Res (2019) pmid: 31405947", "Include": "true"}, {"number": "140", "ReferenceId": "30309915", "FullCitation": "Cristescu R, et al. Science (2018) pmid: 30309915", "Include": "true"}, {"number": "141", "ReferenceId": "30785829", "FullCitation": "Ready N, et al. J. Clin. Oncol. (2019) pmid: 30785829", "Include": "true"}, {"number": "142", "ReferenceId": "29658845", "FullCitation": "Hellmann MD, et al. N. Engl. J. Med. (2018) pmid: 29658845", "Include": "true"}, {"number": "143", "ReferenceId": "29657128", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29657128", "Include": "true"}, {"number": "144", "ReferenceId": "29731394", "FullCitation": "Hellmann MD, et al. Cancer Cell (2018) pmid: 29731394", "Include": "true"}, {"number": "145", "ReferenceId": "33558721", "FullCitation": "Rozeman EA, et al. Nat Med (2021) pmid: 33558721", "Include": "true"}, {"number": "146", "ReferenceId": "32916128", "FullCitation": "Sharma P, et al. Cancer Cell (2020) pmid: 32916128", "Include": "true"}, {"number": "147", "ReferenceId": "19935675", "FullCitation": "Brown CJ, et al. Nat. Rev. Cancer (2009) pmid: 19935675", "Include": "true"}, {"number": "148", "ReferenceId": "18410249", "FullCitation": "Joerger AC, et al. Annu. Rev. Biochem. (2008) pmid: 18410249", "Include": "true"}, {"number": "149", "ReferenceId": "12826609", "FullCitation": "Kato S, et al. Proc. Natl. Acad. Sci. U.S.A. (2003) pmid: 12826609", "Include": "true"}, {"number": "150", "ReferenceId": "20978130", "FullCitation": "Kamada R, et al. J. Biol. Chem. (2011) pmid: 20978130", "Include": "true"}, {"number": "151", "ReferenceId": "28472496", "FullCitation": "Zerdoumi Y, et al. Hum. Mol. Genet. (2017) pmid: 28472496", "Include": "true"}, {"number": "152", "ReferenceId": "17690113", "FullCitation": "Yamada H, et al. Carcinogenesis (2007) pmid: 17690113", "Include": "true"}, {"number": "153", "ReferenceId": "22089350", "FullCitation": "Jha P, et al. Diagn. Mol. Pathol. (2011) pmid: 22089350", "Include": "true"}, {"number": "154", "ReferenceId": "15914282", "FullCitation": "Uno M, et al. Cancer Lett. (2005) pmid: 15914282", "Include": "true"}, {"number": "155", "ReferenceId": "16711514", "FullCitation": "Uno M, et al. Int. J. Biol. Markers () pmid: 16711514", "Include": "true"}, {"number": "156", "ReferenceId": "22844452", "FullCitation": "Lass U, et al. PLoS ONE (2012) pmid: 22844452", "Include": "true"}, {"number": "157", "ReferenceId": "23009112", "FullCitation": "Faria MH, et al. APMIS (2012) pmid: 23009112", "Include": "true"}, {"number": "158", "ReferenceId": "24358143", "FullCitation": "Milinkovic V, et al. PLoS ONE (2013) pmid: 24358143", "Include": "true"}, {"number": "159", "ReferenceId": "23613880", "FullCitation": "Galatro TF, et al. PLoS ONE (2013) pmid: 23613880", "Include": "true"}, {"number": "160", "ReferenceId": "11939587", "FullCitation": "Schmidt MC, et al. J. Neuropathol. Exp. Neurol. (2002) pmid: 11939587", "Include": "true"}, {"number": "161", "ReferenceId": "11550308", "FullCitation": "Nozaki M, et al. Neuro_oncology (1999) pmid: 11550308", "Include": "true"}, {"number": "162", "ReferenceId": "20107315", "FullCitation": "Hirai H, et al. Cancer Biol. Ther. (2010) pmid: 20107315", "Include": "true"}, {"number": "163", "ReferenceId": "21799033", "FullCitation": "Bridges KA, et al. Clin. Cancer Res. (2011) pmid: 21799033", "Include": "true"}, {"number": "164", "ReferenceId": "21389100", "FullCitation": "Rajeshkumar NV, et al. Clin. Cancer Res. (2011) pmid: 21389100", "Include": "true"}, {"number": "165", "ReferenceId": "25504633", "FullCitation": "Osman AA, et al. Mol. Cancer Ther. (2015) pmid: 25504633", "Include": "true"}, {"number": "166", "ReferenceId": "12489850", "FullCitation": "Xu L, et al. Mol. Cancer Ther. (2002) pmid: 12489850", "Include": "true"}, {"number": "167", "ReferenceId": "11713371", "FullCitation": "Xu L, et al. Mol. Med. (2001) pmid: 11713371", "Include": "true"}, {"number": "168", "ReferenceId": "23470564", "FullCitation": "Camp ER, et al. Cancer Gene Ther. (2013) pmid: 23470564", "Include": "true"}, {"number": "169", "ReferenceId": "25240597", "FullCitation": "Kim SS, et al. Nanomedicine (2015) pmid: 25240597", "Include": "true"}, {"number": "170", "ReferenceId": "27357628", "FullCitation": "Pirollo KF, et al. Mol. Ther. (2016) pmid: 27357628", "Include": "true"}, {"number": "171", "ReferenceId": "27601554", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27601554", "Include": "true"}, {"number": "172", "ReferenceId": "27998224", "FullCitation": "Leijen S, et al. J. Clin. Oncol. (2016) pmid: 27998224", "Include": "true"}, {"number": "173", "ReferenceId": "31315834", "FullCitation": "Lee J, et al. Cancer Discov (2019) pmid: 31315834", "Include": "true"}, {"number": "174", "ReferenceId": "29535125", "FullCitation": "M\u00e9ndez E, et al. Clin. Cancer Res. (2018) pmid: 29535125", "Include": "true"}, {"number": "175", "ReferenceId": "34538072", "FullCitation": "Seligmann JF, et al. J Clin Oncol (2021) pmid: 34538072", "Include": "true"}, {"number": "176", "ReferenceId": "22965953", "FullCitation": "Lehmann S, et al. J. Clin. Oncol. (2012) pmid: 22965953", "Include": "true"}, {"number": "177", "ReferenceId": "26086967", "FullCitation": "Mohell N, et al. Cell Death Dis (2015) pmid: 26086967", "Include": "true"}, {"number": "178", "ReferenceId": "27179933", "FullCitation": "Fransson \u00c5, et al. J Ovarian Res (2016) pmid: 27179933", "Include": "true"}, {"number": "179", "ReferenceId": "26563132", "FullCitation": "Kwok M, et al. Blood (2016) pmid: 26563132", "Include": "true"}, {"number": "180", "ReferenceId": "30975914", "FullCitation": "Boudny M, et al. Haematologica (2019) pmid: 30975914", "Include": "true"}, {"number": "181", "ReferenceId": "28062704", "FullCitation": "Dillon MT, et al. Mol. Cancer Ther. (2017) pmid: 28062704", "Include": "true"}, {"number": "182", "ReferenceId": "30127241", "FullCitation": "Middleton FK, et al. Cancers (Basel) (2018) pmid: 30127241", "Include": "true"}, {"number": "183", "ReferenceId": "29165669", "FullCitation": "Landrum MJ, et al. Nucleic Acids Res. (2018) pmid: 29165669", "Include": "true"}, {"number": "184", "ReferenceId": "26014290", "FullCitation": "Bougeard G, et al. J. Clin. Oncol. (2015) pmid: 26014290", "Include": "true"}, {"number": "185", "ReferenceId": "23355100", "FullCitation": "Sorrell AD, et al. Mol Diagn Ther (2013) pmid: 23355100", "Include": "true"}, {"number": "186", "ReferenceId": "11219776", "FullCitation": "Nichols KE, et al. Cancer Epidemiol. Biomarkers Prev. (2001) pmid: 11219776", "Include": "true"}, {"number": "187", "ReferenceId": "9006316", "FullCitation": "Kleihues P, et al. Am. J. Pathol. (1997) pmid: 9006316", "Include": "true"}, {"number": "188", "ReferenceId": "19204208", "FullCitation": "Gonzalez KD, et al. J. Clin. Oncol. (2009) pmid: 19204208", "Include": "true"}, {"number": "189", "ReferenceId": "12672316", "FullCitation": "Lalloo F, et al. Lancet (2003) pmid: 12672316", "Include": "true"}, {"number": "190", "ReferenceId": "31050713", "FullCitation": "Mandelker D, et al. Ann. Oncol. (2019) pmid: 31050713", "Include": "true"}, {"number": "191", "ReferenceId": "25426837", "FullCitation": "Jaiswal S, et al. N. Engl. J. Med. (2014) pmid: 25426837", "Include": "true"}, {"number": "192", "ReferenceId": "25426838", "FullCitation": "Genovese G, et al. N. Engl. J. Med. (2014) pmid: 25426838", "Include": "true"}, {"number": "193", "ReferenceId": "25326804", "FullCitation": "Xie M, et al. Nat. Med. (2014) pmid: 25326804", "Include": "true"}, {"number": "194", "ReferenceId": "28669404", "FullCitation": "Acuna_Hidalgo R, et al. Am. J. Hum. Genet. (2017) pmid: 28669404", "Include": "true"}, {"number": "195", "ReferenceId": "29678827", "FullCitation": "Severson EA, et al. Blood (2018) pmid: 29678827", "Include": "true"}, {"number": "196", "ReferenceId": "29420212", "FullCitation": "Fuster JJ, et al. Circ. Res. (2018) pmid: 29420212", "Include": "true"}, {"number": "197", "ReferenceId": "30504320", "FullCitation": "Hematology Am Soc Hematol Educ Program (2018) pmid: 30504320", "Include": "true"}, {"number": "198", "ReferenceId": "32269342", "FullCitation": "Chabon JJ, et al. Nature (2020) pmid: 32269342", "Include": "true"}, {"number": "199", "ReferenceId": "31768066", "FullCitation": "Razavi P, et al. Nat. Med. (2019) pmid: 31768066", "Include": "true"}, {"number": "200", "ReferenceId": "19850045", "FullCitation": "Zeng J, et al. Gastroenterology (2010) pmid: 19850045", "Include": "true"}, {"number": "201", "ReferenceId": "22615382", "FullCitation": "Chicas A, et al. Proc. Natl. Acad. Sci. U.S.A. (2012) pmid: 22615382", "Include": "true"}, {"number": "202", "ReferenceId": "23722541", "FullCitation": "Teng YC, et al. Cancer Res. (2013) pmid: 23722541", "Include": "true"}, {"number": "203", "ReferenceId": "24716659", "FullCitation": "Li L, et al. Mol. Cancer (2014) pmid: 24716659", "Include": "true"}, {"number": "204", "ReferenceId": "25537453", "FullCitation": "Lin W, et al. Mol. Cancer Res. (2015) pmid: 25537453", "Include": "true"}, {"number": "205", "ReferenceId": "23922798", "FullCitation": "Liang X, et al. PLoS ONE (2013) pmid: 23922798", "Include": "true"}, {"number": "206", "ReferenceId": "23794145", "FullCitation": "Jiping Z, et al. J. Cell. Biochem. (2013) pmid: 23794145", "Include": "true"}, {"number": "207", "ReferenceId": "24200674", "FullCitation": "Vieira FQ, et al. Endocr. Relat. Cancer (2014) pmid: 24200674", "Include": "true"}, {"number": "208", "ReferenceId": "20371346", "FullCitation": "Sharma SV, et al. Cell (2010) pmid: 20371346", "Include": "true"}, {"number": "209", "ReferenceId": "20371339", "FullCitation": "Dannenberg JH, et al. Cell (2010) pmid: 20371339", "Include": "true"}, {"number": "210", "ReferenceId": "22937203", "FullCitation": "Hou J, et al. Am J Transl Res (2012) pmid: 22937203", "Include": "true"}, {"number": "211", "ReferenceId": "23266085", "FullCitation": "Paolicchi E, et al. Crit. Rev. Oncol. Hematol. (2013) pmid: 23266085", "Include": "true"}, {"number": "212", "ReferenceId": "16419055", "FullCitation": "van Zutven LJ, et al. Genes Chromosomes Cancer (2006) pmid: 16419055", "Include": "true"}, {"number": "213", "ReferenceId": "19430464", "FullCitation": "Wang GG, et al. Nature (2009) pmid: 19430464", "Include": "true"}, {"number": "214", "ReferenceId": "25162518", "FullCitation": "Qi L, et al. PLoS ONE (2014) pmid: 25162518", "Include": "true"}, {"number": "215", "ReferenceId": "8521522", "FullCitation": "Quelle DE, et al. Cell (1995) pmid: 8521522", "Include": "true"}, {"number": "216", "ReferenceId": "15878778", "FullCitation": "Mutat. Res. (2005) pmid: 15878778", "Include": "true"}, {"number": "217", "ReferenceId": "9484839", "FullCitation": "Gazzeri S, et al. Oncogene (1998) pmid: 9484839", "Include": "true"}, {"number": "218", "ReferenceId": "10498883", "FullCitation": "Oncogene (1999) pmid: 10498883", "Include": "true"}, {"number": "219", "ReferenceId": "16869746", "FullCitation": "Sherr CJ, et al. Cold Spring Harb. Symp. Quant. Biol. (2005) pmid: 16869746", "Include": "true"}, {"number": "220", "ReferenceId": "20549699", "FullCitation": "Ozenne P, et al. Int. J. Cancer (2010) pmid: 20549699", "Include": "true"}, {"number": "221", "ReferenceId": "10498896", "FullCitation": "Ruas M, et al. Oncogene (1999) pmid: 10498896", "Include": "true"}, {"number": "222", "ReferenceId": "17909018", "FullCitation": "Jones R, et al. Cancer Res. (2007) pmid: 17909018", "Include": "true"}, {"number": "223", "ReferenceId": "18843795", "FullCitation": "Haferkamp S, et al. Aging Cell (2008) pmid: 18843795", "Include": "true"}, {"number": "224", "ReferenceId": "12417717", "FullCitation": "Huot TJ, et al. Mol. Cell. Biol. (2002) pmid: 12417717", "Include": "true"}, {"number": "225", "ReferenceId": "11518711", "FullCitation": "Rizos H, et al. J. Biol. Chem. (2001) pmid: 11518711", "Include": "true"}, {"number": "226", "ReferenceId": "9324288", "FullCitation": "Gombart AF, et al. Leukemia (1997) pmid: 9324288", "Include": "true"}, {"number": "227", "ReferenceId": "7780957", "FullCitation": "Yang R, et al. Cancer Res. (1995) pmid: 7780957", "Include": "true"}, {"number": "228", "ReferenceId": "8668202", "FullCitation": "Parry D, et al. Mol. Cell. Biol. (1996) pmid: 8668202", "Include": "true"}, {"number": "229", "ReferenceId": "12606942", "FullCitation": "Greenblatt MS, et al. Oncogene (2003) pmid: 12606942", "Include": "true"}, {"number": "230", "ReferenceId": "10491434", "FullCitation": "Yarbrough WG, et al. J. Natl. Cancer Inst. (1999) pmid: 10491434", "Include": "true"}, {"number": "231", "ReferenceId": "11255261", "FullCitation": "Poi MJ, et al. Mol. Carcinog. (2001) pmid: 11255261", "Include": "true"}, {"number": "232", "ReferenceId": "9660926", "FullCitation": "Byeon IJ, et al. Mol. Cell (1998) pmid: 9660926", "Include": "true"}, {"number": "233", "ReferenceId": "19260062", "FullCitation": "Kannengiesser C, et al. Hum. Mutat. (2009) pmid: 19260062", "Include": "true"}, {"number": "234", "ReferenceId": "10719365", "FullCitation": "Lal G, et al. Genes Chromosomes Cancer (2000) pmid: 10719365", "Include": "true"}, {"number": "235", "ReferenceId": "7777061", "FullCitation": "Koh J, et al. Nature (1995) pmid: 7777061", "Include": "true"}, {"number": "236", "ReferenceId": "20340136", "FullCitation": "McKenzie HA, et al. Hum. Mutat. (2010) pmid: 20340136", "Include": "true"}, {"number": "237", "ReferenceId": "21462282", "FullCitation": "Miller PJ, et al. Hum. Mutat. (2011) pmid: 21462282", "Include": "true"}, {"number": "238", "ReferenceId": "905385", "FullCitation": "Kutscher CL, et al. Physiol. Behav. (1977) pmid: 905385", "Include": "true"}, {"number": "239", "ReferenceId": "24659262", "FullCitation": "Scaini MC, et al. Hum. Mutat. (2014) pmid: 24659262", "Include": "true"}, {"number": "240", "ReferenceId": "23190892", "FullCitation": "Jenkins NC, et al. J. Invest. Dermatol. (2013) pmid: 23190892", "Include": "true"}, {"number": "241", "ReferenceId": "10389768", "FullCitation": "Walker GJ, et al. Int. J. Cancer (1999) pmid: 10389768", "Include": "true"}, {"number": "242", "ReferenceId": "12853981", "FullCitation": "Rutter JL, et al. Oncogene (2003) pmid: 12853981", "Include": "true"}, {"number": "243", "ReferenceId": "18538737", "FullCitation": "Itahana K, et al. Cancer Cell (2008) pmid: 18538737", "Include": "true"}, {"number": "244", "ReferenceId": "10360174", "FullCitation": "Zhang Y, et al. Mol. Cell (1999) pmid: 10360174", "Include": "true"}, {"number": "245", "ReferenceId": "9529249", "FullCitation": "Zhang Y, et al. Cell (1998) pmid: 9529249", "Include": "true"}, {"number": "246", "ReferenceId": "26824661", "FullCitation": "Ceccarelli M, et al. Cell (2016) pmid: 26824661", "Include": "true"}, {"number": "247", "ReferenceId": "20129251", "FullCitation": "Verhaak RG, et al. Cancer Cell (2010) pmid: 20129251", "Include": "true"}, {"number": "248", "ReferenceId": "23412337", "FullCitation": "Sottoriva A, et al. Proc. Natl. Acad. Sci. U.S.A. (2013) pmid: 23412337", "Include": "true"}, {"number": "249", "ReferenceId": "16909113", "FullCitation": "Weber RG, et al. Oncogene (2007) pmid: 16909113", "Include": "true"}, {"number": "250", "ReferenceId": "11303791", "FullCitation": "Nakamura M, et al. Brain Pathol. (2001) pmid: 11303791", "Include": "true"}, {"number": "251", "ReferenceId": "11489817", "FullCitation": "Chakravarti A, et al. Clin. Cancer Res. (2001) pmid: 11489817", "Include": "true"}, {"number": "252", "ReferenceId": "21713760", "FullCitation": "Feng J, et al. Cancer (2012) pmid: 21713760", "Include": "true"}, {"number": "253", "ReferenceId": "21636552", "FullCitation": "Raabe EH, et al. Clin. Cancer Res. (2011) pmid: 21636552", "Include": "true"}, {"number": "254", "ReferenceId": "21843312", "FullCitation": "Liu W, et al. J. Exp. Clin. Cancer Res. (2011) pmid: 21843312", "Include": "true"}, {"number": "255", "ReferenceId": "21278246", "FullCitation": "Konecny GE, et al. Clin. Cancer Res. (2011) pmid: 21278246", "Include": "true"}, {"number": "256", "ReferenceId": "21871868", "FullCitation": "Katsumi Y, et al. Biochem. Biophys. Res. Commun. (2011) pmid: 21871868", "Include": "true"}, {"number": "257", "ReferenceId": "22711607", "FullCitation": "Cen L, et al. Neuro_oncology (2012) pmid: 22711607", "Include": "true"}, {"number": "258", "ReferenceId": "23898052", "FullCitation": "Logan JE, et al. Anticancer Res. (2013) pmid: 23898052", "Include": "true"}, {"number": "259", "ReferenceId": "28283584", "FullCitation": "Elvin JA, et al. Oncologist (2017) pmid: 28283584", "Include": "true"}, {"number": "260", "ReferenceId": "26715889", "FullCitation": "Gao J, et al. Curr Oncol (2015) pmid: 26715889", "Include": "true"}, {"number": "261", "ReferenceId": "27542767", "FullCitation": "Infante JR, et al. Clin. Cancer Res. (2016) pmid: 27542767", "Include": "true"}, {"number": "262", "ReferenceId": "24797823", "FullCitation": "Johnson DB, et al. Oncologist (2014) pmid: 24797823", "Include": "true"}, {"number": "263", "ReferenceId": "21460101", "FullCitation": "Van Maerken T, et al. Mol. Cancer Ther. (2011) pmid: 21460101", "Include": "true"}, {"number": "264", "ReferenceId": "21725357", "FullCitation": "Gamble LD, et al. Oncogene (2012) pmid: 21725357", "Include": "true"}, {"number": "265", "ReferenceId": "7666917", "FullCitation": "Whelan AJ, et al. N Engl J Med (1995) pmid: 7666917", "Include": "true"}, {"number": "266", "ReferenceId": "20687502", "FullCitation": "Adv Exp Med Biol (2010) pmid: 20687502", "Include": "true"}, {"number": "267", "ReferenceId": "9479083", "FullCitation": "Hogg D, et al. J Cutan Med Surg (1998) pmid: 9479083", "Include": "true"}, {"number": "268", "ReferenceId": "29543703", "FullCitation": "De Unamuno B, et al. Melanoma Res (2018) pmid: 29543703", "Include": "true"}, {"number": "269", "ReferenceId": "26892650", "FullCitation": "Soura E, et al. J Am Acad Dermatol (2016) pmid: 26892650", "Include": "true"}, {"number": "270", "ReferenceId": "29405243", "FullCitation": "Huerta C, et al. Acta Derm Venereol (2018) pmid: 29405243", "Include": "true"}, {"number": "271", "ReferenceId": "8414022", "FullCitation": "Kaufman DK, et al. Neurology (1993) pmid: 8414022", "Include": "true"}, {"number": "272", "ReferenceId": "9622062", "FullCitation": "Bahuau M, et al. Cancer Res (1998) pmid: 9622062", "Include": "true"}, {"number": "273", "ReferenceId": "28699883", "FullCitation": "Chan AK, et al. Clin Neuropathol () pmid: 28699883", "Include": "true"}, {"number": "274", "ReferenceId": "25344362", "FullCitation": "Tolcher AW, et al. Ann. Oncol. (2015) pmid: 25344362", "Include": "true"}, {"number": "275", "ReferenceId": "22706484", "FullCitation": "Hainsworth JD, et al. Clin Adv Hematol Oncol (2012) pmid: 22706484", "Include": "true"}, {"number": "276", "ReferenceId": "25526733", "FullCitation": "Ma DJ, et al. Neuro_oncology (2015) pmid: 25526733", "Include": "true"}, {"number": "277", "ReferenceId": "22160854", "FullCitation": "Mason WP, et al. Invest New Drugs (2012) pmid: 22160854", "Include": "true"}, {"number": "278", "ReferenceId": "19018475", "FullCitation": "Kreisl TN, et al. J. Neurooncol. (2009) pmid: 19018475", "Include": "true"}, {"number": "279", "ReferenceId": "31998633", "FullCitation": "Gojo J, et al. Front Oncol (2019) pmid: 31998633", "Include": "true"}, {"number": "280", "ReferenceId": "27531351", "FullCitation": "Blumenthal DT, et al. J. Neurooncol. (2016) pmid: 27531351", "Include": "true"}, {"number": "281", "ReferenceId": "23066039", "FullCitation": "Janku F, et al. Cancer Res. (2013) pmid: 23066039", "Include": "true"}, {"number": "282", "ReferenceId": "22271473", "FullCitation": "Janku F, et al. J. Clin. Oncol. (2012) pmid: 22271473", "Include": "true"}, {"number": "283", "ReferenceId": "21216929", "FullCitation": "Janku F, et al. Mol. Cancer Ther. (2011) pmid: 21216929", "Include": "true"}, {"number": "284", "ReferenceId": "25878190", "FullCitation": "Moulder S, et al. Ann. Oncol. (2015) pmid: 25878190", "Include": "true"}, {"number": "285", "ReferenceId": "20921209", "FullCitation": "Sarkaria JN, et al. Clin. Cancer Res. (2010) pmid: 20921209", "Include": "true"}, {"number": "286", "ReferenceId": "23099651", "FullCitation": "Lee EQ, et al. Neuro_oncology (2012) pmid: 23099651", "Include": "true"}, {"number": "287", "ReferenceId": "23564811", "FullCitation": "Lassen U, et al. Anticancer Res. (2013) pmid: 23564811", "Include": "true"}, {"number": "288", "ReferenceId": "22033322", "FullCitation": "Geoerger B, et al. Eur. J. Cancer (2012) pmid: 22033322", "Include": "true"}, {"number": "289", "ReferenceId": "24470557", "FullCitation": "Wen PY, et al. Neuro_oncology (2014) pmid: 24470557", "Include": "true"}]}, "Signatures": {"Signature": {"ServerTime": "2022_03_21 21:09:13", "OpName": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director", "Text": "Erik Williams, M.D. | Julia Elvin, M.D., Ph.D., Laboratory Director"}}, "reportProperties": {"reportProperty": [{"identifier": "QualityControlMetrics", "key": "MedianCoverageValue", "value": "857x"}, {"identifier": "AdditionalFindings", "key": "TumorMutationBurdenScore", "value": "5 Muts/Mb"}, {"identifier": "AdditionalFindings", "key": "MicrosatelliteStatusScore", "value": "0 fraction_unstable_loci"}, {"identifier": "AdditionalFindings", "key": "LossOfHeterozygosityScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "BloodTumorMutationalBurdenScore", "value": "Units Not Reported"}, {"identifier": "AdditionalFindings", "key": "TumorFractionScore", "value": "Units Not Reported"}]}, "comments": null, "AAC": {"Amendmends": null}}, "variant_report": {"xmlns": "http://foundationmedicine.com/compbio/variant_report_external", "disease": "BRAIN", "disease_ontology": "Brain glioblastoma (GBM)", "flowcell_analysis": "2000020869", "gender": "female", "pathology_diagnosis": "Glioblastoma", "percent_tumor_nuclei": "60", "pipeline_version": "v3.10.2", "purity_assessment": "65.7", "specimen": "ORD_1321248_01*US1270842.01", "study": "CLINICAL_F1CDx", "test_request": "ORD_1321248_01", "test_type": "FoundationOneDx", "tissue_of_origin": "Brain", "xsischemaLocation": "http://foundationmedicine.com/compbio/variant_report_external http://integration.foundationmedicine.com/reporting/variant_report_external_2.2.xsd", "samples": {"sample": {"bait_set": "DX1", "mean_exon_depth": "873.87", "name": "SQ_US1270842.01_1", "nucleic_acid_type": "DNA"}}, "quality_control": {"status": "Pass"}, "short_variants": {"short_variant": [{"allele_fraction": "0.5906", "cds_effect": "1036G>A", "depth": "811", "equivocal": "false", "functional_effect": "missense", "gene": "NBN", "percent_reads": "59.06", "position": "chr8:90971041", "protein_effect": "V346M", "status": "unknown", "strand": "_", "transcript": "NM_002485", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.3868", "cds_effect": "5819_5822delATAG", "depth": "998", "equivocal": "false", "functional_effect": "frameshift", "gene": "ATRX", "percent_reads": "38.68", "position": "chrX:76855013", "protein_effect": "D1940fs*14", "status": "likely", "strand": "_", "transcript": "NM_000489", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.5353", "cds_effect": "1370_1372delAGG", "depth": "665", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "DAXX", "percent_reads": "53.53", "position": "chr6:33287880", "protein_effect": "E457del", "status": "unknown", "strand": "_", "transcript": "NM_001350", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.3966", "cds_effect": "224G>A", "depth": "464", "equivocal": "false", "functional_effect": "missense", "gene": "NOTCH3", "percent_reads": "39.66", "position": "chr19:15303304", "protein_effect": "R75Q", "status": "unknown", "strand": "_", "transcript": "NM_000435", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.5414", "cds_effect": "2842_2847delACAACA", "depth": "532", "equivocal": "false", "functional_effect": "nonframeshift", "gene": "MAP3K1", "percent_reads": "54.14", "position": "chr5:56177868", "protein_effect": "T948_T949del", "status": "unknown", "strand": "+", "transcript": "NM_005921", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.8841", "cds_effect": "1685C>T", "depth": "414", "equivocal": "false", "functional_effect": "missense", "gene": "TBX3", "percent_reads": "88.41", "position": "chr12:115112055", "protein_effect": "A562V", "status": "unknown", "strand": "_", "transcript": "NM_016569", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.8952", "cds_effect": "817C>T", "depth": "973", "equivocal": "false", "functional_effect": "missense", "gene": "TP53", "percent_reads": "89.52", "position": "chr17:7577121", "protein_effect": "R273C", "status": "known", "strand": "_", "transcript": "NM_000546", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.14", "cds_effect": "7582G>A", "depth": "657", "equivocal": "false", "functional_effect": "missense", "gene": "BRCA2", "percent_reads": "14.0", "position": "chr13:32930711", "protein_effect": "G2528R", "status": "unknown", "strand": "+", "transcript": "NM_000059", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.0214", "cds_effect": "1625A>T", "depth": "1075", "equivocal": "false", "functional_effect": "missense", "gene": "PIK3CA", "percent_reads": "2.14", "position": "chr3:178936083", "protein_effect": "E542V", "status": "known", "strand": "+", "subclonal": "true", "transcript": "NM_006218", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.4017", "cds_effect": "4071_4072insGATT", "depth": "351", "equivocal": "false", "functional_effect": "frameshift", "gene": "MSH6", "percent_reads": "40.17", "position": "chr2:48033987", "protein_effect": "K1358fs*2", "status": "unknown", "strand": "+", "transcript": "NM_000179", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.6132", "cds_effect": "617G>A", "depth": "755", "equivocal": "false", "functional_effect": "missense", "gene": "EPHB4", "percent_reads": "61.32", "position": "chr7:100420084", "protein_effect": "R206Q", "status": "unknown", "strand": "_", "transcript": "NM_004444", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"allele_fraction": "0.4795", "cds_effect": "2103C>A", "depth": "999", "equivocal": "false", "functional_effect": "missense", "gene": "ATR", "percent_reads": "47.95", "position": "chr3:142274957", "protein_effect": "D701E", "status": "unknown", "strand": "_", "transcript": "NM_001184", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}]}, "copy_number_alterations": {"copy_number_alteration": [{"copy_number": "7", "equivocal": "true", "gene": "FGF6", "number_of_exons": "3 of 3", "position": "chr12:4494593_4598143", "ratio": "2.03", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "CCND2", "number_of_exons": "5 of 5", "position": "chr12:4335813_4445571", "ratio": "2.04", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "KDM5A", "number_of_exons": "28 of 28", "position": "chr12:394621_498257", "ratio": "1.96", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "RAD52", "number_of_exons": "11 of 11", "position": "chr12:1022522_1042247", "ratio": "1.87", "status": "unknown", "type": "amplification", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"copy_number": "7", "equivocal": "true", "gene": "FGF23", "number_of_exons": "3 of 3", "position": "chr12:4479508_4488748", "ratio": "2.33", "status": "known", "type": "amplification", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}, {"copy_number": "0", "equivocal": "false", "gene": "CDKN2A", "number_of_exons": "3 of 5", "position": "chr9:21970900_21989026", "ratio": "0.27", "status": "known", "type": "loss", "dna_evidence": {"sample": "SQ_US1270842.01_1"}}]}, "rearrangements": null, "biomarkers": {"microsatellite_instability": {"status": "MSS"}, "tumor_mutation_burden": {"score": "5.04", "status": "low", "unit": "mutations_per_megabase"}}, "non_human_content": null}}}}